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ABSTRACT 
The objective of this thesis is to develop a new method, re-parameterizing the logistic dose-toxicity 
model of the time-to-event continual reassessment method (TITE-CRM) for phase 1 dose-
escalation cancer trials,  to account for patient heterogeneity. 
In a phase 1 dose-escalation clinical trial, the goal is to identify a dose (the maximum 
tolerated dose or MTD) that is associated with a pre-specified probability of unacceptable toxicity.  
TITE-CRM is a Bayesian, model-based dose-escalation trial design specificially intended for 
situations where participants must be observed for toxicity a long period time compared to the rate 
at which patients present for treatment. 
The risk of toxicity may vary due to particpants’ inherent characteristics. For example, 
patients with lung cancer and concomitant renal disease are not able to tolerate the same dose level 
of the cancer treatment as the patients without concomitant renal disease. If patient heterogeneity 
exists, the one-group study design will ignore the patient heterogeneity and give an average MTD, 
which could result in excess toxicity in the higher risk patients and suboptimal dosing in the lower 
risk patients.  
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We have developed a new method to address this issue by re-parameterizing the logisitic 
model of the TITE-CRM and adding dose-escalation rules to reflect risk group ordering 
information and control aggressive dose escalation. We assessed the operating characteristics of 
this design in simulations assuming three risk groups, although the model is trivially extensible to 
a greater number. We compared this method to parallel trials that use independent one-parameter 
logistic models. We investigated scenarios with equal numbers of patients in the risk groups and 
more patients in the higher toxicity risk group, three different true dose-toxicity models and three 
sample sizes, for a total of 5,400 trials. 
According to the results, the TITE-CRM with re-parameterized logistic model used in 3-
group trials performs similarly to the TITE-CRM with one-parameter logistic model used in the 
parallel trials in terms of operating characteristics. However, the TITE-CRM with the re-
parameterized logistic model worked better in terms of in-trial dose allocation of patients and 
recommending the correct final dose in the scenario where there were more patients with higher 
toxicity risk in a trial.  However, estimations of the group risk difference were not precise and the 
coverages of credible intervals of the group difference parameters were excessively conservative. 
The method shows promise, and could be implemented now, but further improvements are 
required. Cancer is one of the major public health concerns in the modern society and the new 
method can be used in the phase 1 dose-escalation cancer trial and have positive impact on the 
public health. 
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1.0  INTRODUCTION 
The purpose of a phase 1 dose-escalation clinical trial is to find the maximum tolerated dose 
(MTD), defined as the highest dose of a drug or treatment associated with unacceptable toxicity in 
a prespecified proportion of patients [1]. Currently, there are algorithm-based designs, such as 3+3, 
and model-based designs, such as the continual assessment method (CRM) [2] for these trials.  
Algorithmic designs such as 3+3 uses a set of prespecified rules to decide the dose level 
for the next cohort of participants, depending on the toxicities observed in the cohort just 
completed. It treats 3 participants at each dose level and raises the dose for the next 3 participants 
if no toxicity is observed; if there is a toxicity, another cohort of 3 participants is treated at the 
same dose level. If there is no toxicity among the 3 additional participants, the next cohort of 3 at 
a dose level up, if there is toxicity, the next cohort of 3 is treated at one dose level down. 
Simulations demonstrate this design will, on average, stop at the dose level at which the probability 
of toxicity is 1/6.  
CRM uses the dosing and toxicity data of all the participants who have been treated to 
decide the dose level of the next participant by means of a mathematical function relating dose to 
toxicity. Compared to the 3+3 method, CRM and other model-based designs are more flexible, in 
that they can accomodate larger sample sizes (improving the precision of estimation) and can be 
calibrated to converge on target probabilities smaller or larger than 1/6, as required by the 
perceived risk-benefit tradeoff (e.g., patients with higher-risk disease may tolerate treatments with 
 2 
higher risk of toxicity), and they tend to treat more patients at doses closer to the MTD [3], which 
improves the efficiency of estimation and potentially provides more effective treatments to the 
participants of the trial. According to a literature review for model-based designs conducted by 
Love [4], model-based designs were used in 1.6% of phase 1 trials published between 1991 and 
2006, increasing to 6.4% in trials published between 2012 and 2014. Although model-based 
designs are not yet as prevalent as the algorithm-based methods, they are becoming more widely 
used.  
CRM is a Bayesian design that has five components: prior; dose-toxicity model; target 
probability of toxicity; pre-specified probability of toxicity at all dose levels; patient doses and 
toxicity already observed. The prior and model reflect the assumed dose-toxicity relationship and 
the certainty it is correct based on the information available before the first patient is treated. The 
first patient is treated at a preselected dose (or treatment level), and, after observing if the patient 
experiences dose-limiting toxicity (DLT) or not, the dose-toxicity curve is fit. The next patient will 
be treated at the dose at which the toxicity probability predicted by the dose-toxicity curve is close 
to the target toxicity probability, subject to rules that moderate the speed of escalation. The step is 
then repeated until the last patient is treated. The number of patients is pre-specified. 
Extended CRM was proposed after O’Quigley’s first introduction of CRM in 1990. 
O’Quigley et al. [5] proposed a two-group likelihood-based CRM in 1999 to determine the MTD 
for two groups with different toxicity risks. In many phase 1 oncology studies, the risk for toxicity 
among patients is different due to variation in disease or other predispositions. For example, it has 
been observed that younger patients better tolerate higher doses of treatment for acute leukemia 
[5]. If patient heterogeneity exists in the study sample, the one-parameter CRM design will ignore 
the patient heterogeneity and give an average estimated MTD. O’Quigley et al.’s proposed two-
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group CRM design applied two-parameter models and maximum likelihood estimation to locate 
the MTD for each group without conducting two separate trials. Economically, a two-group design 
has advantages regarding human and financial resources over conducting two separate trials. Later, 
O’Quigley and Paoletti [6] studied CRM for two groups with ordered risk. In this study, O’Quigley 
and Paoletti included the ordering information into the dose allocation strategy in the first stage 
and the prior for the parameter representing the group difference, to locate the MTD for each group 
more efficiently, especially with small sample sizes.  
The time-to-event continual reassessment method (TITE-CRM) proposed by Cheung and 
Chappell [7] in 2000 is an extension of CRM appropriate for treatments where the toxicities are 
delayed in onset. In most designs, a participant cannot be recruited until the previous participant 
(or the paticipants in the previous cohort) has been fully observed. In trials for cancer treatments 
such as radiation, it may take months to observe an event for a participant, resulting in 
impractically long trials. On the other hand, if the observation period defined in the study protocol 
is not long enough to observe all likely events, some toxicity events will not be considered with 
respect to the dose escalation decision. TITE-CRM manages late-onset toxicities by allowing 
subjects to be enrolled as they present, irrespective of the observational status of patients already 
on trials, thereby increasing trial efficiency. 
Salter et al.[8] further studied the TITE-CRM design with two-parameter models between 
two risk groups using likelihood estimation. The likelihood estimation approach required at least 
one toxic and one non-toxic observation in each group. Hence, a two-stage trial, an initial one-
group dose escalation stage followed by a two-group TITE-CRM stage, was employed to meet the 
requirements in the study. The study results showed that the TITE-CRM can accommodate two 
risk groups with different MTDs within a trial.  
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The objective of our study is to re-parameterize the dose-toxicity model used in the TITE-
CRM among groups (two or more than two) with ordered toxicity risk, using Bayesian estimation. 
In our study, we will use the same rules throughout the study, without separating the trial into 
different stages.  
CRM and TITE-CRM will be reviewed in more details in Section 2. Our study method will 
be described in Section 3. Simulations will be conducted and the results will be presented in 
Section 4. The results are to be further discussed in Section 5.  
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2.0  LITERATURE REVIEW 
CRM was proposed to allocate more patients to dose levels with estimated probability of toxicity 
close to a predefined target probability, to increase the therapeutic benefit in cancer trials at an 
acceptable risk level [2]. While the 3+3 uses the information gathered at the current dose level to 
decide which dose level the next patient will receive, CRM designs use all the information 
available to assess the relationship between dose and toxicity and recommend a dose level for the 
next patient. The methods of CRM and its extensions are reviewed in this section. 
2.1 CRM 
In all phase 1 dose-escalation trials, dose-limiting toxicity is a dichotomous event defined in the 
trial protocol by a class of adverse events (generally characterized in terms of severity of event 
and relatedness to treatment) occurring in a specified time frame starting at the beginning of 
treatment. A patient who has experienced toxicity is denoted by yj=1 and a patient who has not by 
yj=0. Suppose there are k dose levels denoted di (i = 1, …, k) on clinical scale and n patients 
recruited in a trial. Suppose π* denotes the target probability of toxicity, which is assumed to be 
given (generally specified based on assumptions about the costs of likely toxicities compared to 
the perceived benefit of treatment). A function π(x, α) is assumed to describe the relationship 
between dose and the probability of toxicity, where π is monotonic in x and α, where α>0, and x 
is a numerical relabled dose representing clinical dose or treatment level d used in the dose-toxicity 
function, where xi=π(π0i,E(α))-1,{π01,...,π0k} is the skeleton, the expected probabilities of toxicity 
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before any data are collected and E(α) is the expected value of α under the prior. The values x1,...xk 
are not updated as data are collected, instead, the dose-toxicity function is updated. It is assumed 
there exist α and x such that π(x, α) = π*. The true α in the dose-toxicity function is contantly 
estimated by the posterior mean α� when a toxicity outcome is observed. Suppose f(α) is the prior 
distribution of α and contains all the information about the dose-toxicity function at the intitiation 
of the trial. Let xj denote the relabeled dose for jth participant. After we have observed outcomes 
for J patients, the posterior distribution of α is assumed to be Equation (1). Then, we plug posterior 
mean α�, Equation (2), into the dose-toxicity equation to get the plug-in estimates of πiJ+1, Equation 
(3), of the probability of toxicity for each dose level i for the J+1th patient. The recommended 
dose level for patient J+1 will be the level that minimizes (πiJ+1 – π*)2.  
 
These steps are repeated until the last patient has been fully observed.  
According to O’Quigley [2], the prior distribution of the parameter α should reflect the 
knowledge of dose-toxicity before the trial begins. In his study, f(α) = exp(-α) was chosen as the 
prior distribution for its positive parameter space and simplicity; truncated normal and log-normal 
were also considered by O’Quigley. A one-parameter hyperbolic model (4) and a two-parameter 
logistic model were considered as dose-toxicity functions and the operating characteristics were 
compared among these models. In his simulations, he concluded that the one-parameter hyperbolic 
model outperformed the two-parameter logistic model in terms of operating characteristics.  
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The sample size for O’Quigley’s simulation study was 25, as the author considered the 
typical sample sizes of 3+3 trials (generally, 12-18) would be too small. The starting dose was the 
level at which the probability of toxicity was equal to the target probability. The doses given to 
patients were dominated by the CRM. However, the proposed method in the O’Quigley’s study 
cannot be fully practiced in reality due to the patient safety issue of overdose. In typical clinical 
practice, the starting dose is the lowest dose level and no dose should be skipped between two 
adjacent patients for safety considerations. 
O’Quigley’s following study involved point estimation and interval estimation for CRM 
[9], and the mean squared error and normal approximated confidence intervals for both maximum 
likelihood estimators and Bayesian estimators were used to assess the precision of the estimators. 
It was concluded that the simulations for both estimators had similar results and the Bayesian 
estimates and intervals slightly outperformed the maximum likelihood estimates and intervals.  
After the introduction of CRM, Korn et al.[10] conducted a study to compare the CRM and 
the 3+3 and concluded that the CRM trial took too long and tended to treat patients at higher dose 
levels than the true MTD. He suggested recruiting more patients than one at a time at one dose 
level and choosing a dose at which the posterior probability is less than and closest to the target 
probability in the CRM trials.  
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2.2 CRM FOR PATIENT HETEROGENEITY 
2.2.1 CRM for two groups 
As an extension of the original CRM, a two-group continual reassessment method using maximum 
likelihood estimation for patients with toxicity risk heterogeneity was introduced by O’Quigley et 
al. [5] in 1999. The two-group CRM was referred as two-sample CRM. The purpose of the two-
sample CRM was to find the appropriate dose for each group using one working model.  
Suppose there are k dose levels di (i = 1, …, k) and assume two groups share the dose levels. 
Suppose there are n patients that have received doses (j = 1, …, n), where n1 patients are in group 
1 and n-n1 patients are in group 2. Let xj denote the relabeled dose for jth patient and I denote an 
indicator variable for group, I = 1 for group 1 and I = 2 for group 2.  Let yj denote the toxicity 
outcome for the jth patient. The dose-toxicity model satisfies Equation (5), 
  
where π1 is the dose-toxicity equation for group 1 and π2 is the dose-toxicity equation for group 2, 
α represents the common dose-toxicity information shared between groups and β represents the 
group difference. There exists (α, β) such that π1(xi, α) = π* and π2(xl, α, β) = π*, where π* is the 
target toxicity probability. The true α and β were estimated by the maximum likelihood estimators. 
The likelihood for the n observations can be written as Equation (6). 
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The recommended dose for the n+1th patient will be the dose level that minimizes |π1(xn+1, 𝛼𝛼�) - 
π*| if the n+1th patient goes to group 1, and the dose level that minimizes |π2(xn+1, 𝛼𝛼�, ?̂?𝛽) - π*| if 
the n+1th patient goes to group 2, where 𝛼𝛼� and ?̂?𝛽 are the maximum likelihood estimates. 
In the O’Quigley proposal [5], patients were recruited randomly with equal probability to 
two groups. Because their method used maximum likelihood estimation that required 
heterogeneity among patient responses to ensure the existence of maximum likelihood estimate 
[11], a two-stage design was employed, with a first stage similar to the 3+3 dose-escalation design 
and a second stage as CRM. Both groups started at dose level 1 and moved one level up if two 
consecutive non-toxicity outcomes were observed. Dose escalation proceeded separately in the 
two groups until toxicity was observed in both groups and then the trial proceeded as described 
above. 
Two variants of the hyperbolic model (4) used in the original CRM paper shown below 
were used to estimate the probability of toxicity at each dose level.  
 
The sample size was 32, and each group had at least 10 participants. The recommended 
dose level was the one after the last patient was treated. According to the study results, the two-
group CRM performed better than two separate CRM trials or one-merged CRM trial when two 
groups of patients had differences while sharing some common features. 
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2.2.2 CRM for ordered groups 
The two-group CRM was extended further by O’Quigley and Paoletti [6] using patient 
heterogeneity with ordered risk. In the two-sample CRM, the ordering information of the groups 
is unknown. For the ordered group study, the ordering information was included into the design to 
increase trial efficiency. For the two ordered groups, a two-stage design was applied using a model 
that was similar to Equation (5). Patients from the lower risk group were  treated with dose levels 
greater than or equal to the higher risk group in the first-stage dose escalation, until dose limiting 
toxicity was observed. The second stage featured either a maximum likelihood-based or Bayesian 
CRM. The ordering information was included in the prior when Bayesian CRM was applied at the 
second stage. For example, a gamma or normal distribution was used as the prior of β to reflect 
that the risk difference was positive in the study. Given the toxicity risk of group 1 was larger than 
that of group 2, the prior of β should satisfy  
 
where k and k+l are dose levels, l≥0, representing the difference between two dose levels, π* is 
target probability of toxicity, α and µβ are unknown and need to be estimated. If µβ is 0, it is 
assumed that there is no risk difference between the groups and the result depends largely on the 
data. σβ represents the standard deviation of β and reflects how informative the prior is. The larger 
σβ, the vaguer the prior. A set of σβ was tested in the simulation and the impact of prior was 
assessed. 
Results showed that under correct modelling assumptions, the ordered group CRM 
outperformed the two-group likelihood-based CRM. When the assumptions were incorrect and the 
prior was not informative, the ordered group CRM performed better due to the information 
 11 
included in the first-stage dose escalation. When the assumptions were incorrect and the prior was 
informative, the assumptions impacted the running of trial, but the final recommendation dose was 
informative and not incorrect. 
2.3 TITE-CRM 
In the CRM design, a patient is recruited and treated based on the toxicity results of all previously 
treated patients (although small cohorts could be introduced, they are not part of the modeling). If 
the current patient has not experienced DLT or reached the end of observation period, the next 
patient's treatment must be delayed, creating recruitment (eligible patients might not be 
enrollment) and trial management (the trial must be repeatedly opened and closed to accrual) 
issues. TITE-CRM was introduced for clinical trials with late-onset toxicities by Cheung and 
Chappell [7] to deal with this problem.  
Cheung and Chappell extended the CRM by including a weighted dose-response model. In 
their study [7], a weight w, which is a function of the time since treatment, was added to the 
parametric model used in the CRM. Let g(x, w, α) = w·π(x, α), where 0 ≤ w ≤ 1, g is monotonically 
increasing in w, and π(x, α) is the parametric dose-toxicity model. w is the fraction of the 
observation time for patient over the total observation period pre-specified in protocol. Hence, the 
likelihood for weighted CRM for J observations is 
. 
Additionally, Cheung and Chappell used an initial dose escalation stage for both maximum 
likelihood estimation and Bayesian estimation, letting three patients start at the lowest dose level 
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and escalating to the next dose if no toxicity was observed until the first toxicity occurred, then 
switching to TITE-CRM. In their simulated trials, the total observation period was set to 6 months, 
and in the initial stage, 3 patients were recruited at 6-month intervals and in the TITE-CRM stage, 
a patient was recruited every 0.5 months. The power model π(x, α) = xα was used in the simulation. 
An exponential distribution was used for the prior. The patients’ failure times were generated from 
a uniform distribution, log-logistic distribution and Weibull distribution in different simulations. 
The results showed that the correct dose recommendation percentages were similar under failure 
time generated using different distributions. The results of the TITE-CRM were comparable to that 
of the CRM, whereas the trial duration was shortened under the TITE-CRM scheme. The authors 
also suggested that the two-stage designs should be used for safety concern. 
Later, Normolle and Lawrence [12] simulated trials to further study the operating 
characteristics of the one-stage TITE-CRM compared to the 3+3. In their study, a logistic model 
and a normal prior with mean 0 and standard deviation as 0.1 or 0.3 were used for the Bayesian 
TITE-CRM. There was no initial cohorts-of-3 escalation.  The usual rules to control aggressive 
dose escalation in CRM stated in Section 2.1 were applied. Additionally, the rule that dose 
escalation for the next patient was not allowed until the previous patient had experienced DLT or 
had finished the whole observation period without DLT was also added. The sample size was 36. 
The results indicated that TITE-CRM was susceptible to underestimation of toxicity when there 
were abrupt jumps in the true dose-toxicity function. When the assumed dose-toxicity function is 
close to the true state of nature, the toxicity risk for the TITE-CRM was not greater than that for 
the 3+3. 
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2.4 TITE-CRM FOR PATIENT HETEROGENEITY 
Patient heterogeneity regarding toxicity risk exists in phase 1 oncology trials. Previously, 
O’Quigley et al. studied the two-group CRM which was based on the maximum likelihood method. 
In 2015, Salter et al. [8] extended the TITE-CRM to two groups with toxicity risk.  
A two-parameter dose-toxicity model with additive relationship between two groups was 
used,  
 
where I was the indicator variable for group 1 and group 2, g was weighted dose-toxicity function, 
α represented the shared information between two groups and τ represented the difference between 
the two groups. Parameter estimation was based on the maximum likelihood approach and the 
two-stage method proposed by O’Quigley [5] was applied. Therefore, the likelihood after n 
observations is given as: 
 
where n1 the number of patients observed in group 1, n-n1 the number of patients observed in group 
2. The maximum likelihood estimates α� and τ� are the solutions to the Equations (13). 
 
The recommended dose for n+1th patient is the dose level that minimizes |π(xn+1, 𝛼𝛼�) - π*| if n+1th 
patient is in group 1, and the dose level that minimizes |π(xn+1, 𝛼𝛼� + ?̂?𝜏) - π*| if n+1th patient is in 
group 2, where π* is the target probability of toxicity. The steps are repeated until all subjects are 
observed. 
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Empiric functions f(x, α) = xexp(α) and f(x, α+τ) = xexp(α+τ) were used as the dose-toxicity 
functions in the simulation. Sample size was 32, with a balanced scenario of 16 patients in each 
group and an unbalanced scenario of 20 and 12 patients in two groups. The results of the simulation 
comparing the one-group and two-group scenarios showed that the TITE-CRM can accommodate 
two groups with different MTDs using maximum likelihood method and the results were 
comparable, even though the proportion that a true MTD was recommended in the two-group 
scenario was lower than the one-group scenario due to smaller sample sizes.  
2.5 WORKING MODEL AND PRIOR FOR BAYESIAN METHOD 
The studies referenced above used various dose-toxicity models, including the one-parameter 
hyperbolic model (4) which is equivalent to power model π(x, α) = xα, empiric model (14) and 
one-parameter and two-parameter logistic models (15).  
 
For the empiric model (14), θi1 was the initial estimate for the toxicity probability at each dose 
level i, which are determined by physicians based on experience before trial. The logistic model 
(15) is often used due to its flexibility and familiarity to physicians [13]. When β is a constant, 
Equation (15) is an intercept-fixed one-parameter logistic model. When α is a constant, Equation 
(15) is a slope-fixed one-parameter logistic model. When both parameters are not fixed, the 
equation becomes a two-parameter logistic model, which is more flexible than the one-parameter 
logistic model.  
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According to the simulated study, compared to the one-parameter hyperbolic model, the 
empiric model and the logistic model by Chevret [13], the intercept-fixed one-parameter logistic 
model worked better in terms of the probability of identifying the true MTD, especially when the 
intercept was equal to 3 for the logistic model. The study by Chevret [13] showed that when 
intercept was equal to 3, the bias and MSE of estimated probability of DLT were the smallest 
compared to the model with intercept smaller or larger than 3. The study also compared the impact 
of different choices of priors such as Gamma(1,2), Exponential(1), Lognormal(1,2), Uniform(0,3) 
to the CRM and the results showed that as long as the prior was not informative, they had similar 
effects on the CRM.  
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3.0  METHOD 
The objective of this thesis is to re-parameterize the dose-toxicity model used in the TITE-CRM 
to accommodate patients with ordered toxicity risk. In order to introduce ordering information into 
the model, we divided the sample subjects into 2 or more groups according to their toxicity risk 
instead of 2 groups as referenced in the literature [5, 6, 8]. We conducted simulated studies using 
the re-parameterized model and parallel one-parameter models to compare the differences of the 
operating characteristics of one trial with several risk groups versus those of several separate trials. 
The model will be explained and designed using three groups, but the model is easily extended to 
more than three.  
3.1 BAYESIAN ESTIMATION 
Suppose there are k dose levels di (i = 1, …, k) shared among 3 groups of patients and n patients 
are recruited in total. Let yj denote the toxicity outcome for the jth patient. yj takes the value of 0 
for not observing a toxicity event and 1 for observing a toxicity event. Let I denote the group 
indicator, I =1, 2 or 3. Suppose π* is the target probability of toxicity. The dose-toxicity function 
π for the three-group CRM is specified such that 0 ≤ π(x, I) ≤ 1, and π is increasing in x. The dose-
toxicity function for an observation is expressed as P(d, I, y) = π(x, α, δ1, δ2), where α represents 
the shared information among 3 groups, δ1 represents the difference between group 1 and group 2, 
δ2 represents the difference between group 2 and group 3. The ordering of risk of 3 groups is 
reflected in Equation (16):  
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where l denotes the lth group, m denotes the mth dose level. It is assumed that priors of α, δ1, δ2 
are independent of each other.  
For the assumed dose-toxicity function π(xi, α, δ1, δ2), there exist α, δ1, δ2 such that  
π(xk, α) = π(xl, α, δ1) = π(xm, α, δ1, δ2) = π* (k ≥ l ≥ m). The true α, δ1, δ2 in the dose-toxicity 
function are estimated continuously throughout the trial when a toxicity outome is observed or 
not. Because TITE-CRM was used in our study, we added a weight w to the dose-toxicity 
function and let g(x, w, α) = w·π(x, α) denote the weighted dose-toxicity function for group 1, 
g(x, w, α, δ1) for group 2 and g(x, w, α, δ1, δ2) for group 3.  
Suppose f1(α) is the prior distribution of α, f2(δ1) the prior of δ1 and f3(δ2) the prior of δ2, 
and these priors contain the pre-trial information about the dose-toxicity function. The prior joint 
distribution is then f1(α)·f2(δ1)·f3(δ2). After we have observed outcomes for J out of n patients, 
where J1, J2 and J3 are the within-group sample sizes, the joint posterior distribution of α, δ1, δ2 
and posterior mean estimates are as below.  
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Then we substitue α�, 𝛿𝛿1� , 𝛿𝛿2� into the dose-toxicity function π to get the estimate πn+1 at all dose 
levels in all risk groups for n+1th patient. The recommended dose level for the n+1th patient will 
be the level that minimizes |πn+1 – π*| for the group the patient is in. 
3.2 SIMULATION STUDY 
3.2.1 Model re-parameterization 
For the simulation study, we used the intercept-fixed logistic model with intercept equal to 3 based 
on previous studies [13].  Other functions can be used using a similar parametric framework, as 
long as the oredering of the risk group-specific dose-toxicity functions is guaranteed.  The function 
of the logistic model for three groups is given as. 
We assumed there were eight dose levels shared among groups because there were three 
risk groups in the trial and the starting dose levels were different for each group. The probabilities 
of toxicity at each dose in each group that would be given by the physicians at the outset of the 
trial, are in Table 1.  
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Table 1. Assumed probabilities of toxicity 
Dose Group 
1 2 3 
1 0.01 0.014 0.020 
2 0.025 0.034 0.045 
3 0.05 0.065 0.082 
4 0.1 0.125 0.151 
5 0.15 0.181 0.213 
6 0.2 0.235 0.271 
7 0.25 0.289 0.325 
8 0.3 0.34 0.377 
The relabeled doses are given as x1, …, x8. Those for group 1 are determined by inverting 
the first equation in (19) when α=1, that is, xk=log(Pk/(1-Pk))-3 for k=1,...8  and Pk is an entry in 
the second column (Group 1) of Table 1.  The relabeled doses are displayed in Table 2. 
Table 2. Relabeled doses from Table 1 
Dose Relabeled Dose 
1 -7.595120
2 -6.663562
3 -5.944439
4 -5.197225
5 -4.734601
6 -4.386294
7 -4.098612
8 -3.847298
The same relabeled doses from Group 1 are used in all other risk groups.  The difference 
in P(DLT) between Group 1 and 2 is incorporated into the model by determining the value of δ1 
that minimizes the squared differences between the Group 2 skeleton and a dose-toxicity function 
with parameter α-δ1: 
(20)
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The same method is used to get the initial value for δ2 by minimizing the function below with the 
relabeled doses, α (which equals 1) and δ1, (estimated from the Group 2 probabilities and the 
Group 1 relabeled doses) and P(DLT) from Group 3 defined in Table 1: 
  (21) 
We assume independent normal prior of the parameters[6, 12]; δ1 and δ2 are constrained to 
be greater than or equal to 0:  
  (22) 
The hyperparameters in Equation (22) are: 
𝜇𝜇𝛼𝛼 = 1,𝜎𝜎𝛼𝛼 = 0.3, 𝜇𝜇𝛿𝛿1 = 0,𝜎𝜎𝛿𝛿1 = 0.1, 𝜇𝜇𝛿𝛿2 = 0,𝜎𝜎𝛿𝛿2 = 0.1 
The prior for α is relatively uninformative. The standard deviations for δ1 and δ2 are set to 
0.1 to ensure that the probability for toxicity would not become unrealistically low. 
3.2.2 Trial setup 
We conducted 100 simulated trials for three situations: 1) the true probability of toxicity at a dose 
level P(DLT) is the same as the assumptions (Table 1); 2) the true P(DLT) is higher than the 
assumption; 3) the true P(DLT) is higher than the assumption and there is a bigger difference of 
probability between the dose level 4 and 5. The true P(DLT) for group 1 (that is, the probabilities 
of DLT used to simulate toxicities) were manually specified and that for group 2 and 3 were 
calculated based on a pre-specified true α, δ1 and δ2 as indicated in Table 3 using Equation (19). 
The P(DLT) of dose 4 and 5 in simulation 3 were manually set to have a larger difference. We 
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used the assumed probabilities and relabeled dose to estimate the P(DLT) in 3 simulations and 
compared those estimates to the true probabilities. 
 
Table 3. True parameters 
Parameters Sim 1 Sim 2 Sim 3 
α 1 0.94 0.9 
δ1 0.048 0.035 0.078 
δ2 0.042 0.07 0.047 
 
The true probability of toxicity are stated in Table 4 and can be visualized in Figure 1. In 
Figure 1, the brown reference line indicates the target P(DLT). There is a big jump of P(DLT) 
from dose 4 to 5 across the target P(DLT) in simulation 3.  
 
Table 4. True probabilities of toxicity for 3 groups in 3 simulations 
Dose 
Simulation 1 Simulation 2 Simulation 3 
1 2 3 1 2 3 1 2 3 
1 0.01 0.014 0.020 0.016 0.02 0.034 0.021 0.038 0.053 
2 0.025 0.034 0.045 0.037 0.046 0.071 0.047 0.077 0.103 
3 0.05 0.065 0.082 0.07 0.085 0.123 0.087 0.132 0.167 
4 0.1 0.125 0.151 0.132 0.154 0.208 0.127 0.182 0.224 
5 0.15 0.181 0.213 0.19 0.217 0.278 0.237 0.308 0.357 
6 0.2 0.235 0.271 0.245 0.275 0.34 0.279 0.353 0.401 
7 0.25 0.289 0.325 0.299 0.33 0.396 0.334 0.404 0.452 
8 0.3 0.34 0.377 0.351 0.381 0.447 0.386 0.453 0.499 
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Figure 1. True dose-toxicity relationship generated for 3 simulations 
 
The sample sizes were set to be 40, 80 and 120 and each group were constrained to have 
at least 10 patients in all groups at the end of the study. For multi-group studies, sample sizes 
targeting between 15 and 30 participants per risk group should be considered; it is unrealistic to 
expect useful parameter estimates with smaller sample sizes.    
We assumed that patients with different characteristics came to trials at random. The 
toxicity risk factors are pre-specified according to the patient characteristics and the patients can 
be grouped according to their characteristics. As an example, in radiotherapy for lung cancer, 
larger volumes of normal lung tissue exposed to radiation (determined by the radiation treatment 
plan) is associated with greater risk of toxicity. Patients recruited for lung cancer treatment could 
be grouped into several risk groups determined by how much normal lung tissue will be under 
radiation therapy. For our simulation, we considered these as two scenarios: 1. The patients with 
different risk come to each risk group with the same probability (0.33), which means there are 
same number of patients in each risk group; 2. The patients with different risk come to each risk 
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group with different probabilities (0.2, 0.35, 0.45), which means more patients are in the higher 
risk groups.  
Uniform distribution, Unif (0, b), where b is the pre-specified observation days, was used 
to generate the time of arrival. Bernoulli(p) distribution was used to generate toxicity event where 
p is the true probabilities of toxicity of each risk group. 
The same rules used for TITE-CRM [12] and CRM trials were employed in the simulation 
for the highest risk group. Additionally, the following rules were applied to the simulated trials to 
reflect ordering information.  
Suppose there are k dose levels di (i = 1, …, k) shared among groups I (I = 1, 2, 3) and n 
patients xj (j = 1, …, n) recruited in total as mentioned in section 3.1. 
1. The starting dose level is set to 1 for the highest risk group, 2 for the medium risk group 
and 3 for the lowest risk group. If no patient has been treated and observed in group I or any group 
larger than I, the first patient in that group will be assigned to that starting level. 
2. When participant j in group I has completed observation at level di, participant j+1 in 
group I may be assigned to level di+1. 
3. When participant j in group Ij>1 has completed observation at level di, participant j+1 in 
any group less than or equal to Ij may be assigned to level di+1. 
In parallel trials for different risk groups, we applied the usual rules used in TITE-CRM 
trial to constrain aggressive dose escalation [12]. The sample sizes for a separate trial were set as 
13, 26 and 40 for scenario 1. The sample size for separate trials were 8, 16 and 24 for group 1, 14, 
28 and 42 for group 2, and 18, 36, 54 for group 3 for scenario 2. 
Point and interval estimates of α, δ1 and δ2 were calculated by using Gibbs sampling to 
draw samples from the posterior distribution (17) using JAGS (Just Another Gibbs Sampler, v. 
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4.3.0),  called through the R package rjags (v. 4-6) under R v. 3.4.2. The mean of the posterior 
sample was used as the point estimate of parameters. The interval estimates of the parameters were 
the 90% credible intervals from the posterior samples. The point and 90% interval estimates of 
P(DLT) were drawn from the P(DLT) samples calculated using parameter samples. Finally, the 
estimates for the last observation in each trial were used for analysis. A sample of R code and jags 
code for the simulation is provided in Appendix B.  
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4.0  RESULTS 
We conducted the simulation study using two scenarios for both a group trial and a parallel trial. 
For scenario 1, there were same number of patients in each risk group. For scenario 2, there were 
more patients in the higher risk groups. For each scenario, we performed 3 simulations and for 
each simulation, we performed 100 trials for each of three different sample sizes. The results were 
analyzed and compared in terms of the estimated parameters and P(DLT), the MTD 
recommendation, the in-trial dose distribution and the distribution of DLTs. The sections that 
contain the results for each situation are summarized in Table 5. 
 
Table 5. Sections of results corresponding to each situation 
 Results Section 
Scenario 1 Estimation: 4.1.1 
    Group trials α 4.1.1.1 
 δ1 4.1.1.2 
 δ2 4.1.1.3 
 P(DLT) 4.1.1.4 
 MTD recommendation 4.1.1.5 
 In-trial dose distribution 4.1.1.6 
 Distribution of DLT 4.1.1.7 
    Parallel trials Estimation: 4.1.2 
Group 1 α 4.1.2.1 
Group 2 α 4.1.2.2 
Group 3 α 4.1.2.3 
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Table 5 Cont’d 
 P(DLT) 4.1.2.4 
 MTD recommendation 4.1.2.5 
 In-trial dose distribution 4.1.2.6 
 Distribution of DLT 4.1.2.7 
Scenario 2 Estimation: 4.2.1 
    Group trials α 4.2.1.1 
 δ1 4.2.1.2 
 δ2 4.2.1.3 
 P(DLT) 4.2.1.4 
 MTD recommendation 4.2.1.5 
 In-trial dose distribution 4.2.1.6 
 Distribution of DLT 4.2.1.7 
    Parallel trials Estimation: 4.2.2 
Group 1 α 4.2.2.1 
Group 2 α 4.2.2.2 
Group 3 α 4.2.2.3 
 P(DLT) 4.2.2.4 
 MTD recommendation 4.2.2.5 
 In-trial dose distribution 4.2.2.6 
 Distribution of DLT 4.2.2.7 
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4.1 SCENARIO 1: EQUAL NUMBER OF PATIENTS IN EACH RISK GROUP 
4.1.1 Group trials 
4.1.1.1 Estimation of α 
The distribution of estimated α is displayed in Figure 2. The black square represents the true α in 
each simulation. As sample size increases, the range of the α estimates gets narrower, and the 
median and mean sample α get closer to the true α. The difference between mean estimated α and 
true α is the smallest in simulation 3, where there is an abrupt jump in P(DLT) between dose 4 and 
5. 
Figure 2. Distribution of estimated α in group trials 
Black squares represent the true α and red hearts represent sample means. 
The box indicates 25th, 50th and 75th percentiles and whisker limits show 
the minimum and maximum. The dots are outliers. 
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Figure 3. Coverage of 90% credible interval of true α in group trials 
The coverage of the 90% credible interval of true α is displayed in Figure 3. The coverage 
of α for group trials is above or around 90% in all simulations of all sizes, indicating a good quality 
of interval estimation.  
4.1.1.2 Estimation of δ1
The distribution of estimated δ1 is displayed in Figure 4. The black square represents the true δ1 in 
each simulation. As sample size increases, the range of δ1 estimates remains wide. The median 
and mean sample δ1 get closer to the true δ1 in simulation 3 only. 
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Figure 4. Distribution of estimated δ1 in group trials 
Figure 5. Coverage of 90% credible interval of true δ1 in group trials 
The coverage of 90% credible interval of δ1 is close to 100% due to wide credible intervals, 
indicating an imprecise estimation of δ1.  
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4.1.1.3 Estimation of δ2
The distribution of estimated δ2 is displayed in Figure 6. The black square represents the true δ2 in 
each simulation. As sample size increases, the range of δ2 estimates still remains wide. The median 
and mean sample δ2 get closer to the true δ2 in simulation 2 only. The true values are less than the 
sample mean in all situations. 
Figure 6. Distribution of estimated δ2 in group trials 
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Figure 7. Coverage of 90% credible interval of true δ2 in group trials 
The coverage of 90% credible interval of δ2 is 100% due to the wide credible intervals, 
indicating an imprecise estimation of δ2.  
4.1.1.4 Estimation of P(DLT) 
Figure 8. Distribution of estimated P(DLT) for group trials. 
The black triangle refers to the true P(DLT) 
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The distribution of P(DLT) is displayed in Figure 8. The black triangle represents the true P(DLT) 
in each group at each dose level. The range of estimates gets narrower as sample size increases in 
each simulation. The mean P(DLT)s are close to the true P(DLT)s except for dose 4 and 5 in 
simulation 3.  
Figure 9. Coverage of 90% credible interval of true P(DLT) for group trials (equal number of patients in each 
risk group) 
The coverage of the 90% credible intervals of true P(DLT) at each dose in each group are 
displayed in Figure 9. The coverages of true P(DLT) at most doses in all simulations for all sample 
sizes are around or above 90%, except the estimated P(DLT) at dose 5 in simulation 3. As the 
sample size increases in simulation 3, the coverage of true P(DLT) at dose 5 in simulation 3 seems 
to be getting worse, while the coverage of true P(DLT) at dose 4 is becoming better. One possible 
reason is the big difference of P(DLT) between dose 4 and dose 5. The method cannot produce a 
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good estimate of P(DLT) at dose 5 in simulation 3 probably because, as the sample size increases, 
more patients are assigned to dose 4 at which the P(DLT) is around 0.2, much less toxic than dose 
5.  
4.1.1.5 MTD recommendation 
The proportion of trials in which the true MTD is recommended is summarized in Figure 10. The 
largest dose with P(DLT) ≤ target P(DLT) in the graph below refers to the maximum dose level at 
which the P(DLT) ≤ 0.2 in a group in a trial. The proportion of trials in a single simulation that the 
recommended dose level is the MTD is displayed.  In simulation 1, most trials recommend the true 
MTD in group 2 and 3 while most trials in group 1 tend to recommend a higher or lower dose level 
than the true MTD with different sample sizes. In simulation 2, most trials in group 2 recommend 
the true MTD and most trials in group 3 recommend a lower dose level than the true MTD with 
all sample sizes, while most trials in group 1 recommend the true MTD for sample size 40 and 80. 
In simulation 3, the sample size 80 has the best result in terms of the proportion of trials 
recommending the true MTD. Most trials with sample size 120 in simulation 3 tend to recommend 
a lower dose level than the true MTD for group 1 and 3, because dose level 5 in simulation 3 for 
sample size 120 see most DLTs as Figure 12 shows. Ideally, the highest proportion of trials should 
recommend the true MTD, but it is acceptable from a safety perspective to recommend a slightly 
lower dose level than the true MTD. 
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Figure 10. Proportion of trials recommending the true MTD for group trials (equal number of patients in each 
risk group) 
Triangles represent the true MTD at which P(DLT) is around 0.2. Largest dose with P(DLT) ≤ target P(DLT) 
4.1.1.6 In-trial dose distribution 
Dose allocation of patients in a trial is one of the operating characteristics. As we stated previously, 
a major advantage of CRM is that more patients in the trial are allocated to dose levels close to the 
MTD. The in-trial dose allocation of patients in group trials is shown in Figure 11. The proportion 
in the graph represents the proportion of patients in a group of a trial allocated to a specific dose 
level. The true MTD in our study is defined as the dose level at which the true P(DLT) is closest 
to target P(DLT) and is represented by a triangle in the graphs. 
As sample size increases, more patients are assigned to the true MTD in 3 groups. As shown 
in the graph, many patients in group 3 simulation 3 are assigned to a lower dose level than the true 
MTD. The reason is the wide difference between dose 4 and 5, and our method chose the safer 
dose level for the patients. According to our pre-specified true probabilities of toxicity, if the true 
MTD is defined as the dose level at which the P(DLT) is closest to but less than the target P(DLT), 
then dose level 3 will be the true MTD for the group 3 in simulation 3.  
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Figure 11. In-trial dose allocation of patients in group trials (equal number of patients in each risk group) 
Triangles represent the true MTD at which P(DLT) is around 0.2. 
4.1.1.7 In-trial DLT distribution 
The amounts of DLTs per trial are summarized in Figure 12. The proportions of DLTs per trial are 
summarized in Figure 13. There are more DLTs in trials as sample size increases as Figure 12 
shows. In Figure 13, the mean DLT proportion is around or below 0.2.  
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Figure 12. DLTs at all dose levels in group trials (equal number of patients in each risk group) 
The error bars represent 25th and 75th percentiles. The dots represent the median numbers of DLTs. 
Figure 13. DLT proportion per trial in group trials (equal number of patients in each risk group) 
The error bars represent 25th and 75th quantiles. Blue dots represent the mean proportions and red hearts 
represent the median proportions. 
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4.1.2 Parallel trials 
4.1.2.1 Estimation of α of group 1 
The distribution of estimated α of group 1 is displayed in Figure 14. The black square represents 
the true α in each simulation. As sample size increases, the range of α estimates gets narrower, 
and the median and mean sample α get closer to, but still higher than the true α.  
Figure 14. Distribution of estimated α of group 1 in parallel trials 
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Figure 15. Coverage of 90% credible interval of true α of group 1 in parallel trials 
The coverage of 90% credible interval of true α is displayed in Figure 15. The coverage of 
α for is getting closer to 90% in all simulations as sample size increases, indicating a good quality 
of interval estimation.  
4.1.2.2 Estimation of α of group 2 
Figure 16 shows the distribution of estimated α in group 2. As sample size increases, the range of 
α estimates gets narrower, and the median and mean sample α get closer to the true α. Simulation 
3 has the largest range of sample α. In Figure 17, the coverage of 90% credible interval of true α 
is getting closer to 90% as sample goes from 13 to 26. The coverage is farther from 0.9 when 
sample size is 40 than 26. 
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Figure 16. Distribution of estimated α of group 2 in parallel trials 
Figure 17. Coverage of 90% credible interval of true α of group 2 in parallel trials 
40 
4.1.2.3 Estimation of α of group 3 
Figure 18 shows the distribution of estimated α in group 3. As sample size increases, the range of 
α estimates gets narrower, and the median and mean sample α get closer to the true α.  
Figure 18. Distribution of estimated α of group 3 in parallel trials 
Figure 19. Coverage of 90% credible interval of true α of group 3 in parallel trials 
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According to Figure 19, sample size of 26 has the best coverage of 90% credible intervals 
among all three sample sizes. 
4.1.2.4 Estimation of P(DLT) 
The distribution of estimated P(DLT) of 3 groups in parallel trials is displayed in Figure 20. The 
black triangles are the true P(DLT) in each group at each dose level. The range of estimated 
P(DLT) at each dose level in each simulation gets narrower and the median P(DLT) is getting 
closer to the true P(DLT) as sample size increases. The true P(DLT) is close to the third quantile 
of estimated P(DLT) at dose 5 in simulation 3, indicating the estimated P(DLT) might not be very 
precise in this situation. 
Figure 20. Distribution of estimated P(DLT) in parallel trials 
The black triangles refer to the true P(DLT)s. 
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Figure 21. Coverage of 90% credible interval of true P(DLT) in parallel trials (equal number of patients in 
each risk group) 
The coverages of true P(DLT) at most doses in all simulations for sample sizes 26 and 40 
are around 85% to 95%. The credible intervals of P(DLT) for sample size 13 are too wide, 
indicating low precision. As the sample size increases the coverages are getting better, except that 
of dose 5 in simulation 3.  
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4.1.2.5 MTD recommendation 
Figure 22. Proportion of trials recommending the true MTD for parallel trials (equal number of patients in 
each risk group) 
As Figure 22 shows, most trials recommend the true MTD in simulation 1 with smallest sample 
size. As sample size increases, most trials for group 1 in all simulations tend to recommend a 
higher dose level, and most trials in group 3 tend to recommend a lower dose level in simulation 
3.
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4.1.2.6 In-trial dose distribution 
 
Figure 23. In-trial dose allocation of patients in parallel trials (equal number of patients in each risk group) 
 
When sample size is small, most patients are assigned to lower dose levels than true MTD. As 
sample size increases, more patients are given the true MTD doses. For the largest sample size, a 
lot of patients in group 1 are assigned to dose level 8. 
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4.1.2.7 DLT distribution 
 
Figure 24. DLTs at all dose levels in parallel trials (equal number of patients in each risk group) 
 
 
 
Figure 25. DLT proportion in a trial for parallel trials (equal number of patients in each risk group) 
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The DLT proportion in most simulations are around and below 0.2. The DLT proportion of group 
3 in simulation 3 with sample size 40 is higher than the average DLT proportion in 3-group trial, 
probably because more patients are assigned to dose level 4 and above.  
4.2 SCENARIO 2: MORE PATIENTS ARE IN HIGHER RISK GROUPS 
Simulation studies of scenario 2 were performed to explore the effect of more patients with higher 
toxicity risk. Additionally, as we use rules to include ordering information, the higher risk groups 
should provide more information than the lower risk group. Hence, it is expected to observe more 
rapid dose-escalation in the lower risk groups.  
The sample size for the parallel trials are 8, 16 and 24 for group 1, 14, 28 and 42 for group 
2, and 18, 36, 54 for group 3. In the following graphic results, sample 1 refers to the smallest 
sample size for each group, sample 2 the medium sample size and sample 3 the largest sample 
size. 
4.2.1 Group trials 
4.2.1.1 Estimation of α 
The distribution of the estimated α is displayed in Figure 26. The black square represents the true 
α in each simulation. As sample size increases, the range of α estimates gets narrower, and the 
median and mean sample α get closer to, but still higher than the true α. It is noted that the 
difference between mean estimated α and true α is the smallest in simulation 3, where there is an 
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abrupt jump in P(DLT) between dose 4 and 5. The ranges of α estimates are similar in all 
simulation for one sample size.  
Figure 26. Distribution of estimated α in group trials 
The coverage of 90% credible interval of true α is displayed in Figure 27. The coverage of 
α is around 90% for all simulations.  
Figure 27. Coverage of 90% credible interval of true α in group trials 
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4.2.1.2 Estimation of δ1
Figure 28. Distribution of estimated δ1 in group trials 
Figure 29. Coverage of 90% credible interval of true δ1 in group trials 
The mean sample δ1 is close to true δ1 in simulation 3 only. In the first and second simulation, the 
true value is much lower than the estimated δ1. As the sample size increases, the ranges of sample 
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δ1 do not get narrower.The coverage of 90% credible interval of true δ1 is 100% due to wide 
credible intervals.  
4.2.1.3 Estimation of δ2
Figure 30. Distribution of estimated δ2 in group trials 
Figure 31. Coverage of 90% credible interval of true δ2 in group trials 
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The mean sample δ2 is close to true δ2 in simulation 2 only. In the first and third simulation, the 
true value is much lower than the mean δ2. As the sample size increases, the ranges of sample δ2 
do not get narrower. The coverage of 90% credible interval of true δ2 is 100% due to wide credible 
intervals. 
4.2.1.4 Estimation of P(DLT) 
Figure 32. Distribution of estimated P(DLT) for group trials 
The black triangle refers to the true P(DLT). 
The distribution of estimated P(DLT) is displayed in Figure 32. The black triangles are the true 
P(DLT). The range of estimated P(DLT) at each dose level in each simulation gets narrower and 
the median P(DLT) is getting close to the true P(DLT) as sample size increases. The median 
sample P(DLT) is much lower than the true for group 1 in simulation 2, compared to the rest 
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situations. The true P(DLT) is close to the third quantile of estimated P(DLT) at dose 5 in 
simulation 3, indicating the estimated P(DLT) might not be very precise in this case. 
Figure 33. Coverage of 90% credible interval of true P(DLT) in group trials 
The coverages of true P(DLT) in each simulation are not getting better as sample size 
increases. Most coverages are around 85% to 97%.  
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4.2.1.5 MTD recommendation 
Figure 34. Proportion of trials recommending the true MTD in group trials (more patients in higher risk 
groups) 
As Figure 34 shows, most trials recommend the true MTD except group 3 in simulation 3 and 
group 1 in simulation 1 with the smallest sample size. In simulation 3, where there is an abrupt 
rise of P(DLT) between dose 4 and 5, dose 4 is the largest safe dose with P(DLT) < 0.2. It is 
acceptable to have a lower level recommended in this case from a safety perspective. 
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4.2.1.6 In-trial dose distribution 
Figure 35. In-trial dose allocation of patients in 3-group trials (more patients in higher risk groups) 
The in-trial dose allocation of patients is shown in Figure 35. Groups 1 and 2 see a more rapid 
dose-escalation, since more full observations in the higher risk group provide dose-toxicity 
information to lower risk groups. For simulation 1, there are too many patients are assigned to 
higher dose level such as level 8 in group 1. 
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4.2.1.7 DLT distribution 
Figure 36. DLTs at all dose levels in group trials (more patients in higher risk groups) 
Figure 37. DLT proportion in a trial for group trials (more patients in higher risk groups) 
The number of DLTs in a trial are summarized in Figure 36. The proportion of DLTs in a trial are 
summarized in Figure 37. The mean proportion of DLTs is around or below 0.2. 
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4.2.2 Parallel trials 
4.2.2.1 Estimation of α of group 1 
Figure 38. Distribution of estimated α of group 1 in parallel trials 
Figure 39. Coverage of 90% credible interval of true α of group 1 in parallel trials 
56 
The distribution of estimated α of group 1 is displayed in Figure 38. The black square 
represents the true α in each simulation. As sample size increases, the interquartile range of α 
estimates gets narrower, and the median and mean sample α get closer to the true α. The coverage 
of 90% credible interval of true α is displayed in Figure 39. The coverage of α is around 90% for 
larger sample sizes. The coverage of α of the first sample size is large due to wide credible intervals 
and small sample size. 
4.2.2.2 Estimation of α of group 2 
Figure 40. Distribution of estimated α of group 2 in parallel trials 
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Figure 41. Coverage of 90% credible interval of true α of group 2 in parallel trials 
The distribution of estimated α of group 2 is displayed in Figure 40. As sample size 
increases, the range of α estimates gets narrower, and the median and mean sample α get closer to 
the true α. The coverage of α is around 90%. The coverage of α is better in group 2 due to larger 
sample size. 
4.2.2.3 Estimation of α of group 3 
Figure 42. Distribution of estimated α of group 3 in parallel trials 
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Figure 43. Coverage of 90% credible interval of true α of group 3 in parallel trials 
The distribution of estimated α of group 3 is displayed in Figure 42. As sample size 
increases, the range of α estimates gets narrower. The sample mean α and the true α overlap for 
the largest sample. The coverage of α is around 90%. The coverage of α is better in group 2 and 3 
due to larger sample size. 
4.2.2.4 Estimation of P(DLT) 
Figure 44. Distribution of estimated P(DLT) in parallel trials 
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The distribution of estimated P(DLT) is displayed in Figure 44. The black triangles are the true 
P(DLT). The range of estimated P(DLT) at each dose level in each simulation gets narrower and 
the median P(DLT) is getting closer to the true P(DLT) as sample size increases. The true P(DLT) 
is close to the third quantile of estimated P(DLT) at dose 5 in simulation 3, indicating the estimated 
P(DLT) might not be very precise in this case. 
Figure 45. Coverage of 90% credible interval of true P(DLT) in parallel trials 
The coverages of true P(DLT) at are getting better as sample size increases. Most coverages are 
around 85% to 95% for medium and large sample sizes. The coverages of sample 1 so high because 
smaller sample size compared to the rest samples. 
4.2.2.5 MTD recommendation 
The proportion of trials that the true MTD is recommended is summarized in Figure 46. In 
simulation 1 with the least sample size, most trials in group 1 recommend a lower dose level than 
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the true MTD while most trials in group 2 recommend a higher dose level than the true MTD. As 
sample size increases, most trials recommend the true MTD in group 1 and 3 while most trials in 
group 2 recommend a higher dose level than the true MTD. In simulation 2, most trials in group 1 
and 2 with the least and largest sample size recommend the true MTD while most trials in group 
3 recommend a level next to the true MTD as the MTD. In simulation 3, most trials in group 2 and 
3 recommend the true MTD while most trials in group 1tend to recommend higher dose level than 
the true MTD. 
Figure 46. Proportion of trials recommending the true MTD in parallel trials (more patients in higher risk 
groups) 
4.2.2.6 In-trial dose distribution 
The in-trial dose allocation of patients is shown is Figure 47. For smallest sample size, there is a 
great portion of patients assigned to suboptimal dose levels. The distribution of patients of sample 
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size 2 and 3 are similar, largest portion of patients are assigned to the true MTD, except for group 
3 in simulation 3 where most trials recommend dose 4 as the true MTD due to safety.  
Figure 47. In-trial dose allocation of patients in parallel trials (more patients in higher risk groups) 
4.2.2.7 DLT distribution 
The numbers of DLTs are summarized in Figure 48. The proportion of DLTs in a trial are 
summarized in Figure 49. The mean DLT proportion in a trial is around or below 0.2. Group 1 has 
the lowest DLT proportion per trial possibly because of the smaller sample sizes. 
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Figure 48. DLTs at all dose levels in parallel trials (more patients in higher risk groups) 
Figure 49. DLT proportion in a trial for parallel trials (more patients in higher risk groups) 
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5.0  DISCUSSION 
In this thesis, we re-parameterized the one-parameter logistic model used in the TITE-CRM dose-
escalation trials to account for patient heterogeneity and studied the operating characteristics of 
the re-parameterized model. Based on the results of the simulations, parameter α is well estimated 
in all simulations in both group trials using three-parameter logistic model and parallel trials using 
one-parameter logistic model. However, the estimations of δ1 and δ2 of the 3-parameter model are 
not as good as that of α. The point estimates are not close to the true values and the credible 
intervals are too wide. Possible reasons for the imprecise estimation could be either the prior for 
δ1 and δ2 are too informative or the estimation is more focused on α - δ1 than δ1. In the future, 
following methods could be used for imporvements:  
1. Try different dose-toxicity models such as power model with various prior settings.
2. Try different ways of reparameterizing the logistic model, such as adding the
difference variable to the intercept of logistic model.
3. Use the posterior median instead of mean as the parameter estimator for δ1 and δ2
because the sample data for both parameters are skewed.
Both group trials and parallel trials achieved a good coverage of true P(DLT) in simulation 
1 and 2. However, estimating the true P(DLT) did not perform well when there was a big jump of 
true P(DLT) between the adjacent two dose levels in simulation 3. 
The results when recommending the correct MTD were somewhat similar in both group 
trials and parallel trials when there were same number of patients in each group. However, when 
there were more high risk patients in a trial, the result of correct final recommendation in group 
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trials was better than the parallel trials in terms of the proportion of trials that recommended the 
true MTD. Generally, the parallel trials tend to recommend higher dose levels than the group trials. 
Additionally, when there were more high risk patients in a trial, the final recommendation resulted 
in group trials seemed to be better than when there were same number of patients in each group in 
terms of the proportion of trials that recommended the true MTD.  
Regarding the in-trial dose distribution of patients, more patients were assigned to a more 
effective dose levels in group trials than the parallel trials in both scenarios, especially when there 
were more patients with higher risk of toxicity in a trial. More patients were allocated to a dose 
level of or close to the true MTD when the sample size was 26 or above in a parallel trial. 
The proportion of patients experiencing DLT in group trials and parallel trials were both 
around 0.2 in all simulations, except that proportion of patients experiencing DLT in the parallel 
trial for simulation 3 group 3 with the largest sample size. From the simulation results, we can see 
that TITE-CRM tended to allocate patients to higher dose levels as sample size increased. Hence, 
it is not surprising to see a higher proportion of DLT in the larger-sample-sized trials. However, 
in reality a phase 1 dose-escalation trial does not recruit that many subjects and DLT should not 
be an issue in the TITE-CRM trials with dose-escalation constraining rules mentioned in section 
3. 
The new method can be applied to the phase 1 dose-escalation trial for patients with 
different toxicity risk to estimate the MTD for each risk group. The method uses TITE-CRM which 
can shorten the trial and increase the trial efficiency. Compared to the previous TITE-CRM method 
with two groups [8], this method does not separate a trial into two stages. Rules to control rapid 
dose-escalation and to reflect ordering information are implemented in the design and are 
conducted throughout the trial. 
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However, the thesis work only used a fixed intercept logistic dose-toxicity model. Other 
commonly models previously metioned could be used for this purpose. Moreover, when using the 
logistic model, there are not many appropriate options for the prior. Future work could incorporate 
different prior settings into this new method. 
In summary, the TITE-CRM with re-parameterized logistic model performs acceptably in 
accommodating patient heterogeneity in a trial in terms of operating characteristics. There are 
improvements that can be made for more precise estimation of true dose-toxicity relationship 
accommodating patient toxicity risk difference. Different dose-toxicity models with various prior 
settings or different ways of re-parameterization or using the posterior median as estimate can be 
studied to see if more precise estimation could be achieved for the risk difference between groups. 
PUBLIC HEALTH SIGNIFICANCE 
Cancer is one of the major public health concerns in the modern society. The clinical trial is the 
gold standard to test the safety and efficacy of cancer treatments. The phase 1 clinical trial is the 
initial stage at which the safety of the treatment is tested and the recommended dose is located. 
Our study reparameterized the logistic dose-toxicity model to identify the shared information and 
differences among different risk groups, and located the maximum tolerated dose (MTD) for each 
risk group. Using the new method in the phase 1 dose-escalation cancer trials could give patients 
in different risk groups a recommended dose with maximum effectiveness at a corresponding 
acceptable toxicity level, which can reduce the number of patients exposed to a suboptimal dose 
or a too toxic dose. In conclusion, the method will have a positive impact on public health. 
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APPENDIX A: ACRONYMS 
3+3: A rule-based dose-escalation method. Treat 3 patients at each dose level, escalate and de-
esclate dose level based on the toxicity outcome of the previous cohort of 3 patients.  
CRM: Continual Reassement Method 
DLT: Dose Limiting Toxicity 
MTD: Maximum Tolerated Dose 
P(DLT): Probability of a DLT at a dose level 
TITE-CRM: Time-to-Event Continual Reassessment Method 
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APPENDIX B: PROGRAMMING CODE 
B.1 CODE FOR SIMULATION
B.1.1 R code (R 3.4.2)
rm(list=ls()) 
library(rjags) 
library(plyr) 
n.core <- 10
library(doMC); registerDoMC(n.core)
setwd("/ihome/dnormolle/xis54/script")
#------------------------------------------------------------------------#
# I. Simulation
#----------get random numbers
seeds <- sample(1:100, n.core, replace=F)
#---alphahat function calls the JAGS program to estimate alpha and delta
based on the doses, dlts and days of #observation
w <- foreach(i.core =
1:n.core,.verbose=T,.errorhandling='stop',.export=ls(.GlobalE
nv),.packages=c('rjags','plyr')) %dopar% { 
set.seed(seeds[i.core]) 
alphahat <- 
function(levs,dlt,ndays,ts,priorstd1,priorstd2,obsdays,tite,group) { 
N <- length(levs) 
dosage <- ts[levs[]] 
w <- rep(1,N) 
if (tite=="Y" | tite=="y") { 
w[dlt==0 & ndays<obsdays] <- ndays[dlt==0 & ndays<obsdays]/obsdays 
} 
data <-  
list(N=N,precision1=1/priorstd1/priorstd1,precision2=1/priorstd2/priorst
d2,dose=dosage,dlt=dlt,w=w,cohort=group) 
inits <- list(alpha1=1,delta1=delta1[1],delta2=delta2[1]) 
n.mcmciter <- 5000
sink(file="/dev/null")
model <- jags.model("titecrm-3-
parameter.jags",data=data,inits=inits,n.adapt=n.mcmc
iter,n.chains=4,quiet=T) 
update(model,n.iter=n.mcmciter,quiet=T) 
samples <- 
jags.samples(model,c("alpha1","delta1","delta2"),n.iter=n.mcmciter,quiet
=T,n.chains=4) 
sink() 
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#---Return ahat, d1hat, d2hat 
ahat <- mean(samples$alpha1) 
ahat.05 <- quantile(samples$alpha1, 0.05,na.rm = T) 
ahat.95 <- quantile(samples$alpha1, 0.95,na.rm = T) 
  
delta1hat <- mean(samples$delta1) 
d1hat.05 <- quantile(samples$delta1, 0.05,na.rm = T) 
d1hat.95 <- quantile(samples$delta1, 0.95,na.rm = T) 
  
delta2hat <- mean(samples$delta2) 
d2hat.05 <- quantile(samples$delta2, 0.05,na.rm = T) 
d2hat.95 <- quantile(samples$delta2, 0.95,na.rm = T) 
  
alphas <- cbind(samples$alpha1[1:(n.mcmciter*4)], 
samples$alpha1[1:(n.mcmciter*4)]-
samples$delta1[1:(n.mcmciter*4)], 
samples$alpha1[1:(n.mcmciter*4)]-
samples$delta1[1:(n.mcmciter*4)]-
samples$delta2[1:(n.mcmciter*4)]) 
 p <- array(NA,dim=c(n.mcmciter*4,nlevel,ncohort)) 
 for(i in 1:nrow(alphas)){  
   for(j in 1:ncohort){ 
     for(k in 1:nlevel){ 
p[i,k,j] <- 
(exp(3+alphas[i,j]*ts1[k]))/(1+exp(3+alphas[i,j]*ts1[k])) 
     } 
   }   
 } 
psummary <- data.frame(matrix(0, ncol = 6, nrow = 
nlevel*ncohort),stringsAsFactors = F) 
names(psummary) <- c("mean","p.05","median","p.95","cohort","dose") 
psummary$dose <- rep(1:nlevel,ncohort) 
psummary$cohort <- rep(1:ncohort,each=nlevel) 
for(i in 1:ncohort){ 
 for(j in 1:nlevel){ 
psummary$mean[psummary$cohort==i&psummary$dose==j] 
<- mean(p[,j,i],na.rm = T) 
psummary$p.05[psummary$cohort==i&psummary$dose==j] 
<- quantile(p[,j,i], 0.05,na.rm = T) 
psummary$median[psummary$cohort==i&psummary$dose==
j] <- quantile(p[,j,i], 0.5,na.rm = T) 
psummary$p.95[psummary$cohort==i&psummary$dose==j] 
<- quantile(p[,j,i], 0.95, na.rm = T) 
   } 
 } 
  
list(ahat,delta1hat,delta2hat,ahat.05,ahat.95,d1hat.05,d1hat.95,d2hat.
05,d2hat.95,psummary) 
} 
 
#----------------------------------------------------------------------# 
#---assign.dose assigns the dose to the newly presented (this.id) 
patient, based on the accumulated data, by calling alphahat  
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assign.dose <- 
function(this.id,id,dose,date.on,dlt.date,level1,obsdays,obsp
eriod,obstype,pi.target,adm.marg,priorstd1,priorstd2,pi.0,tit
e,cohort) { 
 
#-------The first patient is treated at level1 
  if (sharing==0){ 
     if (this.id==1) { 
      if (cohort[this.id]==(ncohort-2)){ 
        trt <- 3} 
      if (cohort[this.id]==(ncohort-1)){ 
        trt <- 2} 
      if (cohort[this.id]==ncohort){ 
        trt <- 1} 
      alpha1.est <- 1 
f.delta1 <- function(delta1) (sum((pi.0[,ncohort-1]-
exp(3+(alpha1.est-delta1)*ts1)/(1+exp(3+(alpha1.est-
delta1)*ts1)))^2)) 
delta1.est <- optimize(f.delta1, c(0, 1), tol = 0.000001, 
maximum=FALSE)$minimum 
f.delta2 <- function(delta2) (sum((pi.0[,ncohort]-
exp(3+(alpha1.est-delta1.est-
delta2)*ts1)/(1+exp(3+(alpha1.est-delta1.est-
delta2)*ts1)))^2)) 
delta2.est <- optimize(f.delta2, c(0, 1), tol = 0.000001, 
maximum=FALSE)$minimum 
ahat.05 <- 0 
ahat.95 <- 0 
d1hat.05 <- 0 
d1hat.95 <- 0 
d2hat.05 <- 0 
d2hat.95 <- 0 
psummary <- NA 
     } 
     
    #-------Otherwise, 
 if (this.id>1) { 
  all <- data.frame(id,dose,date.on,dlt.date,cohort) 
     npats <- this.id-1 
       all <- all[1:npats,] 
       today <- date.on[this.id] 
     all$dlt <-  as.numeric(all$dlt.date<=today) 
       nlevel <- dim.pi.0[1] 
 
    #-------Add number of days patients have been on study to all 
  all$ndays <- obsdays 
       all$ndays[all$dlt==0] <- today - all$date.on[all$dlt==0] 
       all$ndays[all$ndays>obsdays] <- obsdays 
     
    #-------Estimate alpha & beta given current data  
  ests <- alphahat(all$dose,all$dlt,all$ndays,ts, 
priorstd1,priorstd2,obsdays,tite,all$cohort) 
alpha1.est <- ests[[1]] 
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delta1.est <- ests[[2]] 
delta2.est <- ests[[3]] 
ahat.05 <- ests[[4]] 
ahat.95 <- ests[[5]] 
d1hat.05 <- ests[[6]] 
d1hat.95 <- ests[[7]] 
d2hat.05 <- ests[[8]] 
d2hat.95 <- ests[[9]] 
psummary <- ests[[10]] 
alpha.now <- c(alpha1.est,alpha1.est-delta1.est,alpha1.est-
delta1.est-delta2.est) 
#-------Determine number of patients, number of days and number of 
#complete  
#-------patients at each level and put them in data frame expose 
  expose <- array(0,dim=c(nlevel,ncohort,2))  
       for (i.all in 1:nrow(all)) { 
expose[all[i.all,]$dose,all[i.all,]$cohort,2] <- 
expose[all[i.all,]$dose,all[i.all,]$cohort,2] + 
all[i.all,]$ndays 
if (all[i.all,]$ndays>=obsdays | all[i.all,]$dlt==1) 
expose[all[i.all,]$dose,all[i.all,]$cohort,1] <- 
           expose[all[i.all,]$dose,all[i.all,]$cohort,1] + 1 
        } 
     
    #-------calculate pi.now     
        pi.now <- matrix(rep(NA,ncohort*nlevel),ncol=ncohort) 
        for (col in 1:ncohort) { 
pi.now[,col] <- 
(exp(3+alpha.now[col]*ts1))/(1+exp(3+alpha.now[col]*
ts1)) 
        } 
        
    #-------assign first dose to each cohort  
if(is.element(cohort[this.id],head(cohort,n=this.id-1))==FALSE) 
{ 
          if (cohort[this.id]==(ncohort-2)){ 
            trt <- 3} 
          if (cohort[this.id]==(ncohort-1)){ 
            trt <- 2} 
          if (cohort[this.id]==ncohort){ 
            trt <- 1} 
        } 
     
    #-------assign second and following doses to each cohort    
    #-------Calculate P(DLT) given current estimate of alpha & beta 
          
if(cohort[this.id] %in% head(cohort,n=this.id-1)) { 
 
    #-------Select dose based on alpha & beta estimate and the RULES 
    # First, just based on alpha and beta 
    trt <- 0 
    for (d in 1:nlevel) { 
if (pi.now[d,cohort[this.id]]<=pi.target+adm.marg) {trt <- 
d} 
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       } 
 
all <- all[order(all$date.on),] 
l.d.a <- rep(NA,ncohort) 
l.d.a[cohort[this.id]] <- 
tail(all[which(all$cohort==cohort[this.id]),],n=1)$dose 
 
#-------RULE 1:  Jump only one dose between patients 
if (trt > l.d.a[cohort[this.id]]+1){ 
trt <- l.d.a[cohort[this.id]]+1} 
#-------RULE 2:  If a lower dose needs more exposure, 
lodose <- 
head(all[which(all$cohort==cohort[this.id]),],n=1)$dose 
       if (any(all$dose<level1)) { 
        lodose <- min(all$dose,na.rm=T) 
        level1 <- lodose 
       } 
if (trt>lodose) { 
sflag <- 0 
       
    #-----------Count complete patients    
   if (obstype==1) { 
       for (d in lodose:(trt-1)) { 
if (sflag==0 & 
expose[d,cohort[this.id],1]<obsperiod) { 
trt <- d 
sflag <- 1 
        } 
       }  
      } #---End obstype==1 
       
    #-----------Count observation periods    
if (obstype==2) { 
       for (d in lodose:(trt-1)) { 
if (sflag==0 & 
expose[d,cohort[this.id],2]<obsdays*obsper
iod) { 
         trt <- d 
         sflag <- 1 
        } 
       } 
      } #---End obstype==2 
     } #--End trt>lodose 
     
#-------If trt=0, set it to the lowest dose until k patients #observed.  
       if (trt == 0 & this.id <= k) { 
         trt <- 1 
       } 
} #--End of assign 2nd and following dose to each cohort 
    } #---End this is at least the second patient 
  } #--End of sharing == 0 
 
###----------------------------------------------------------------###   
if (sharing==1){ 
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    if (this.id==1) { 
       
      if (cohort[this.id]==(ncohort-2)){ 
        trt <- 3} 
      if (cohort[this.id]==(ncohort-1)){ 
        trt <- 2} 
      if (cohort[this.id]==ncohort){ 
        trt <- 1} 
       
alpha1.est <- 1 
f.delta1 <- function(delta1) (sum((pi.0[,ncohort-1]-
exp(3+(alpha1.est-delta1)*ts1)/(1+exp(3+(alpha1.est-
delta1)*ts1)))^2)) 
delta1.est <- optimize(f.delta1, c(0, 1), tol = 0.000001, 
maximum=FALSE)$minimum 
f.delta2 <- function(delta2) (sum((pi.0[,ncohort]-
exp(3+(alpha1.est-delta1.est-
delta2)*ts1)/(1+exp(3+(alpha1.est-delta1.est-
delta2)*ts1)))^2)) 
delta2.est <- optimize(f.delta2, c(0, 1), tol = 0.000001, 
maximum=FALSE)$minimum 
       
      ahat.05 <- 0 
      ahat.95 <- 0 
      d1hat.05 <- 0 
      d1hat.95 <- 0 
      d2hat.05 <- 0 
      d2hat.95 <- 0 
      psummary <- NA 
    } #-- end of this.id ==1 
     
    #-------Otherwise, we have to think  
     
    if (this.id>1) { 
       
all <- data.frame(id,dose,date.on,dlt.date,cohort) 
      npats <- this.id-1 
      all <- all[1:npats,] 
      today <- date.on[this.id] 
      all$dlt <-  as.numeric(all$dlt.date<=today) 
      nlevel <- dim.pi.0[1] 
 
      #-------Add number of days patients have been on study to all 
       
      all$ndays <- obsdays 
      all$ndays[all$dlt==0] <- today - all$date.on[all$dlt==0] 
      all$ndays[all$ndays>obsdays] <- obsdays 
       
      #-------Estimate alpha & beta given current data  
       
      ests <- alphahat(all$dose,all$dlt,all$ndays,ts, 
                       priorstd1,priorstd2,obsdays,tite,all$cohort) 
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      alpha1.est <- ests[[1]] 
      delta1.est <- ests[[2]] 
      delta2.est <- ests[[3]] 
      ahat.05 <- ests[[4]] 
      ahat.95 <- ests[[5]] 
      d1hat.05 <- ests[[6]] 
      d1hat.95 <- ests[[7]] 
      d2hat.05 <- ests[[8]] 
      d2hat.95 <- ests[[9]] 
      psummary <- ests[[10]] 
      alpha.now <- c(alpha1.est,alpha1.est-delta1.est,alpha1.est-
delta1.est-delta2.est) 
       
#-------Determine number of patients, number of days and number of 
#complete  patients at each level and #put them in data frame expose 
       
      expose <- array(0,dim=c(nlevel,ncohort,2))  
      for (i.all in 1:nrow(all)) { 
expose[all[i.all,]$dose,all[i.all,]$cohort,2] <- 
expose[all[i.all,]$dose,all[i.all,]$cohort,2] 
+all[i.all,]$ndays 
if (all[i.all,]$ndays>=obsdays | all[i.all,]$dlt==1) 
expose[all[i.all,]$dose,all[i.all,]$cohort,1] <- 
expose[all[i.all,]$dose,all[i.all,]$cohort,1] + 1 
      } 
       
      #-------calculate pi.now     
      pi.now <- matrix(rep(NA,ncohort*nlevel),ncol=ncohort) 
      for (col in 1:ncohort) { 
pi.now[,col] <- 
(exp(3+alpha.now[col]*ts1))/(1+exp(3+alpha.now[col]*ts1)) 
      } 
       
      #-------assign first dose to each cohort   
       if(is.element(cohort[this.id],head(cohort,n=this.id-1))==FALSE) { 
         if (cohort[this.id]==(ncohort-2)){ 
           trt <- 3} 
         if (cohort[this.id]==(ncohort-1)){ 
           trt <- 2} 
         if (cohort[this.id]==ncohort){ 
           trt <- 1} 
          
         if (obstype==1) { 
           for(i in 1:(this.id-1)){ 
if (expose[dose[i],cohort[i],1]>obsperiod & 
cohort[this.id]<cohort[i]) {trt <- dose[i]} 
           } 
         } 
         if (obstype==2) { 
           for(i in 1:(this.id-1)){ 
if (expose[dose[i],cohort[i],2]>obsdays*obsperiod & 
cohort[this.id]<cohort[i]) {trt <- dose[i]} 
           } 
         } 
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        } #end of assigning first dose to each cohort when this.id >1 
       
#-------assign second and following doses to each cohort    
  #-------Calculate P(DLT) given current estimate of alpha & delta 
       
      if(cohort[this.id] %in% head(cohort,n=this.id-1)) { 
         
#-------Select dose based on alpha & beta estimate and the RULES 
        #First, just based on alpha and beta 
         
        trt <- 0 
         
        for (d in 1:nlevel) { 
          if (pi.now[d,cohort[this.id]]<=pi.target+adm.marg) {trt <- d} 
        } 
 
        all <- all[order(all$date.on),] 
        l.d.a <- rep(NA,ncohort) 
l.d.a[cohort[this.id]] <- 
tail(all[which(all$cohort==cohort[this.id]),],n=1)$dose 
 
#-------RULE 1:  Jump only one dose between patients within a #cohort 
#(rule 1 will be overridden by rule 2 and 3 if there is a conflict) 
 
          if (trt > l.d.a[cohort[this.id]]+1){ 
              trt <- l.d.a[cohort[this.id]]+1 
          } 
 
#-------RULE 2:  If a lower dose needs more exposure, go there 
         
        lodose <- 
head(all[which(all$cohort==cohort[this.id]),],n=1)$dose 
if 
(any(all$dose<head(all[which(all$cohort==cohort[this.id]),],n=1)
$dose)) { 
          lodose <- min(all$dose,na.rm=T) 
level1 <- lodose 
         } 
         
        if (trt>lodose) { 
          sflag <- 0 
           
         #-----------Count complete patients   
           
          if (obstype==1) { 
            for (d in lodose:(trt-1)) { 
              if (sflag==0 & expose[d,cohort[this.id],1]<obsperiod) { 
                trt <- d 
                sflag <- 1 
              } 
            }  
          } #---End obstype==1 
           
         #-----------Count observation periods    
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          if (obstype==2) { 
            for (d in lodose:(trt-1)) { 
if (sflag==0 & 
expose[d,cohort[this.id],2]<obsdays*obsperiod) { 
trt <- d 
sflag <- 1 
              } 
            } 
          } #---End obstype==2 
        } #--End trt>lodose 
    
             
#-------RULE 3: The dose level of lower risk dose are not lower than 
#the most recent higher risk dose level. 
         
        if (obstype==1) { 
          for(i in 1:(this.id-1)){ 
if (expose[dose[i],cohort[i],1]>obsperiod & 
cohort[this.id]<cohort[i] & dose[i]>trt) {trt <- 
dose[i]+1} 
          } 
        } 
        if (obstype==2) { 
          for(i in 1:(this.id-1)){ 
if (expose[dose[i],cohort[i],2]>obsdays*obsperiod & 
cohort[this.id]<cohort[i] & dose[i]>trt) {trt <- 
dose[i]+1} 
          } 
        } 
         
        if (trt > nlevel) {trt <- nlevel} 
          
#-------If trt=0, set it to the lowest dose until k patients observed.  
        if (trt == 0 & this.id <= k) { 
          trt <- 1 
        } 
        
      } #--End of assign 2nd and following dose to each cohort 
    } #---End this is at least the second patient 
  } #--End of sharing == 1   
   
   
list(trt,alpha1.est,delta1.est,delta2.est,ahat.05,ahat.95,d1hat.05,d1hat
.95,d2hat.05,d2hat.95,psummary) 
} #---End assign.dose 
 
#----------------------------------------------------------------------# 
#---Trial Descriptors 
# tite is the trial TITE-CRM (Y/N) 
# level1 is the first dose level 
# obsdays is the number of days the participants are observed for DLT 
# obsperiod is the multiple of units must be observed at a level prior 
#to escalation to the next level 
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# obstype 1:  units=completed patients  2:  units=observation periods 
# pi.target is the target rate 
# target dose is the highest dose with P(DLT)<pi.target+adm.marg.  Set 
#adm.marg to 0 
# to never exceed target rate (very conservative) 
# priorstd is the standard deviation on the prior.  Ususally 0.3 for 
#alpha. Set 0.1 for delta 
# n.max is the number of patients/trial 
# recruit.days is the number of days to recruit n.max patients 
# pi.0 is the assumed skeleton 
# sharing is the whether or not the rules of ordering information are 
#applied 
# k is the least number of patients to be treated in a trial, control 
#for failed trial 
# a1, d1 and d2 are true parameters pre-specified 
 
tite <- "Y" 
level1 <- 2 
obsdays <- 42 
obsperiod <- 1 
obstype <- 2 
pi.target <- 0.2 
adm.marg <- 0.05 
priorstd1 <- 0.3 
priorstd2 <- 0.1 
sharing <- 1 
a1 <- c(1,0.94,0.9) 
d1 <- c(0.048,0.035,0.078) 
d2 <- c(0.042,0.07,0.047) 
 
#---define n.max and id and at least k patients receiving treatment in 
#each trial.  
 
n.max <- 80 
id <- 1:n.max 
k <- 10 
recruit.days <- 600 
 
#---Rescale dose and P(DLT) 
 
pi.0.1 <- c(0.01,0.025,0.05,0.1,0.15,0.2,0.25,0.3) 
ts1 <- log(pi.0.1/(1-pi.0.1))-3 
 
pi.0.2 <- exp(3+(a1[1]-d1[1])*ts1)/(1+exp(3+(a1[1]-d1[1])*ts1)) 
pi.0.3 <- exp(3+(a1[1]-d1[1]-d2[1])*ts1)/(1+exp(3+(a1[1]-d1[1]-
d2[1])*ts1)) 
pi.0 <- cbind(pi.0.1,pi.0.2,pi.0.3) 
dim.pi.0 <- dim(pi.0) 
nlevel <- dim.pi.0[1] 
 
#----------------------------------------------------------------------# 
 
#---Simulation Controls 
# 
 77 
# n.sim is the number of simulation skeletons 
# Number the skeletons pi.1, etc. and concatenate them into the matrix 
#pi.true.all 
# n.trial is the number of trials per skeleton 
 
n.sim <- 3 
ncohort <- 3 
pi.1 <- pi.0 
 
pi.2.1 <- c(0.016,0.037,0.07,0.132,0.19,0.245,0.299,0.351) 
ts2 <- (log(pi.2.1/(1-pi.2.1))-3)/a1[2] 
pi.2.2 <- exp(3+(a1[2]-d1[2])*ts2)/(1+exp(3+(a1[2]-d1[2])*ts2)) 
pi.2.3 <- exp(3+(a1[2]-d1[2]-d2[2])*ts2)/(1+exp(3+(a1[2]-d1[2]-
d2[2])*ts2)) 
pi.2 <- cbind(pi.2.1,pi.2.2,pi.2.3) 
 
pi.3.1 <- c(0.021,0.047,0.087,0.127,0.237,0.279,0.33,0.38) 
ts3 <- (log(pi.3.1/(1-pi.3.1))-3)/a1[3] 
pi.3.2 <- exp(3+(a1[3]-d1[3])*ts3)/(1+exp(3+(a1[3]-d1[3])*ts3)) 
pi.3.3 <- exp(3+(a1[3]-d1[3]-d2[3])*ts3)/(1+exp(3+(a1[3]-d1[3]-
d2[3])*ts3)) 
pi.3 <- cbind(pi.3.1,pi.3.2,pi.3.3) 
 
pi.true.all <- array(c(pi.1,pi.2,pi.3),c(nlevel,ncohort,n.sim) ) 
 
ts.all <- cbind(ts1,ts2,ts3) 
 
n.trial <- 10 
#----------------------------------------------------------------------# 
#---Simulation loop. If assign.dose returns 0, stop.flag is set to 1 and 
no more doses are assigned for that trial 
 
for (i.sim in 1:n.sim) { 
 pi.true <- pi.true.all[,,i.sim] 
 sim <- rep(i.sim,n.max) 
 starget <- rep(pi.target,n.max) 
 core <- rep(i.core,n.max) 
 ts <- ts.all[,1] 
  
 for (i.trial in 1:n.trial) { 
   
  dose <- rep(0,n.max) 
  date.on <-ceiling(sort(runif(n.max,0,recruit.days))) 
  dlt <- rep(NA,n.max) 
  alpha1 <- rep(NA,n.max) 
   delta1 <- rep(NA,n.max) 
  delta2 <- rep(NA,n.max) 
  alpha1.05 <- rep(NA,n.max) 
alpha1.95 <- rep(NA,n.max) 
  delta1.05 <- rep(NA,n.max) 
  delta1.95 <- rep(NA,n.max) 
  delta2.05 <- rep(NA,n.max) 
  delta2.95 <- rep(NA,n.max) 
  dlt.date <- rep(9999,n.max) 
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  cohort<- sample(1:3,n.max,replace = T) 
  trial <- rep(i.trial,n.max) 
psum <- 
data.frame(matrix(NA,nrow=ncohort*nlevel*n.max,ncol=10)) 
colnames(psum) <- 
c("mean","p.05","median","p.95","cohort","dose","id","trial","
sim","core") 
  psum$core <- i.core 
  psum$sim <- i.sim 
  psum$trial <- i.trial 
  stop.flag <- 0 
     
  for (this.id in 1:n.max) { 
   if (stop.flag==0) { 
hat <- 
assign.dose(this.id,id,dose,date.on,dlt.date,level1,ob
sdays,obsperiod,obstype,pi.target,adm.marg,priorstd1,p
riorstd2,pi.0,tite,cohort) 
dose[this.id] <- hat[[1]] 
alpha1[this.id] <- hat[[2]] 
delta1[this.id] <- hat[[3]] 
delta2[this.id] <- hat[[4]] 
alpha1.05[this.id] <- hat[[5]] 
alpha1.95[this.id] <- hat[[6]] 
delta1.05[this.id] <- hat[[7]] 
delta1.95[this.id] <- hat[[8]] 
delta2.05[this.id] <- hat[[9]] 
delta2.95[this.id] <- hat[[10]] 
psum[((this.id-
1)*ncohort*nlevel+1):(this.id*ncohort*nlevel),1:6] <- 
hat[[11]] 
psum$id[((this.id-
1)*ncohort*nlevel+1):(this.id*ncohort*nlevel)] <- 
this.id 
   } 
     
   if (dose[this.id]>0 & stop.flag==0) { 
dlt[this.id] <- 
rbinom(1,1,pi.true[dose[this.id],cohort[this.id]]) 
if (dlt[this.id]==1) dlt.date[this.id] <-  
date.on[this.id]+ceiling(runif(1,0,obsdays)) 
   } else { 
    stop.flag <- 1 
   } 
  } # end of this.id loop 
 
this.trial <-  
data.frame(core,sim,trial,cohort,id,dose,date.on,dlt,dlt.date,
alpha1,delta1,delta2,alpha1.05,alpha1.95,delta1.05
,delta1.95,delta2.05,delta2.95,starget)  
 
  if (i.sim==1 & i.trial==1) { 
   all.trial <- this.trial 
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  } else { 
   all.trial <- rbind(all.trial,this.trial) 
  } 
 
   
  if (i.sim==1 & i.trial==1) { 
    all.psum <- psum 
  } else { 
    all.psum <- rbind(all.psum,psum) 
  } 
  print(paste("sim=",i.sim,"  trial=",i.trial,sep=""),quote=F) 
 }# end of i.trial loop 
}# end of i.sim loop 
 
all.trial$dlt.date[all.trial$dlt.date==9999] <- NA 
 
#----------------------------------------------------------------------# 
#---Determine proportion of trials that fail.   
 
trial.fail <- 
ddply(all.trial,.(core,sim,trial),summarise,fail=any(dose==0)) 
 
all.trial <- merge(all.trial,trial.fail,by=c("core","sim","trial")) 
 
ok.trial <- all.trial[!all.trial$fail,] 
list(all.psum,trial.fail,all.trial,ok.trial) 
} # end of i.core loop 
 
# merge datasets from different cores 
all.pi <- w[[1]][[1]] 
for (i.core in 2:n.core) { 
  all.pi <- rbind(all.pi,w[[i.core]][[1]]) 
} 
 
all.fail <- w[[1]][[2]] 
for (i.core in 2:n.core) { 
  all.fail <- rbind(all.fail,w[[i.core]][[2]]) 
} 
 
all.trial <- w[[1]][[3]] 
for (i.core in 2:n.core) { 
  all.trial <- rbind(all.trial,w[[i.core]][[3]]) 
} 
 
ok.trial <- w[[1]][[4]] 
for (i.core in 2:n.core) { 
  ok.trial <- rbind(ok.trial,w[[i.core]][[4]]) 
} 
#------------------------------------------------------------------------# 
# export datasets needed 
write.csv(all.trial, "3cohort_all_trial80.csv",row.names = FALSE) 
write.csv(ok.trial, "3cohort_oktrial80.csv",row.names = FALSE) 
write.csv(all.fail, "3cohort_failtrial80.csv",row.names = FALSE) 
write.csv(all.pi, "3cohort_all_pi80.csv",row.names = FALSE) 
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B.1.2 JAGS code (JAGS 4.3.0) 
model { 
 for ( i in 1:N ){ 
  p[i] <- 
(w[i]*exp(3+alpha[cohort[i]]*dose[i]))/(1+exp(3+alpha[cohort[i]]*dose[i])) 
  dlt[i] ~ dbern(p[i]) 
  } 
alpha <- c(alpha1,alpha1-delta1,alpha1-delta1-delta2)  
 alpha1 ~ dnorm(1,precision1) 
 delta1 ~ dnorm(0,precision2) T(0, ) 
 delta2 ~ dnorm(0,precision2) T(0, ) 
} 
B.2 CODE FOR ANALYSIS  
B.2.1 R code (R 3.4.2) 
library(plyr) 
library(dplyr) 
library(ggplot2) 
 
#---Clear leftover variables out 
 
rm(list=ls()) 
 
all.trial <- read.csv("3cohort_all_trial.csv") 
trial.fail <- read.csv("3cohort_failtrial.csv") 
ok.trial <- read.csv("3cohort_oktrial.csv") 
all.psum <- read.csv("3cohort_all_pi.csv") 
 
#I. Data management in general 
# manage ok.trial 
 
oktrial.number1 <- 
ddply(ok.trial,.(sim,core),summarise,trial.number=length(unique(trial))) 
oktrial.number <- 
ddply(oktrial.number1,.(sim),summarise,trial.number=sum(trial.number)) 
ok.trial <- 
ok.trial[order(ok.trial$sim,ok.trial$core,ok.trial$trial,ok.trial$id),] 
 
for(i in 1:n.sim){ 
ok.trial$tr[ok.trial$sim==i] <- 
rep(1:oktrial.number$trial.number[i],each=n.max) 
} 
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# manage all.psum 
all.psum <- 
all.psum[order(all.psum$sim,all.psum$core,all.psum$trial,all.psum$id),] 
for(i in 1:n.sim){ 
  all.psum$tr[all.psum$sim==i] <- rep(1:n.trial,each=n.max*nlevel*ncohort) 
} 
 
#---calculate mean interarrival time for one trial 
interArrival <- rep(NA,n.max-1) 
for(i in 2:n.max){ 
  interArrival[i-1] <- all.trial$date.on[i]-all.trial$date.on[i-1] 
} 
interArrival.bar <- mean(interArrival) 
 
# II.Analysis of operation characteristics based on 100 trials per 
#simulation for group trials. Three simulations in total. 
 
# 1. Compare true pi and estimated pi for diagnostics. 
 
# ---data management for pi.true  
for (i in 1:nrow(ok.trial)) { 
ok.trial$pi.true[i] <- 
pi.true.all[ok.trial$dose[i],ok.trial$cohort[i],ok.trial$sim[i]] 
} 
 
#create a dataset for pi.true 
piTrue <- data.frame(matrix(nrow=nlevel*ncohort*n.sim, ncol=4)) 
colnames(piTrue) <- c("sim","cohort","dose","pi") 
piTrue$sim <- rep(1:n.sim,each=nlevel*ncohort) 
piTrue$cohort <- rep(1:ncohort,each=nlevel) 
piTrue$dose <- rep(1:nlevel) 
for(i.sim in 1:n.sim){ 
  for(i.cohort in 1:ncohort){ 
    for(i.dose in 1:nlevel){ 
piTrue$pi[piTrue$sim==i.sim&piTrue$cohort==i.cohort&piTrue$dose==i
.dose] <- pi.true.all[i.dose,i.cohort,i.sim] 
    } 
  } 
} 
 
## -- True RP2D 
### 1. rp2d is the dose of which pi <= pi.target 
for(i.sim in 1:n.sim){ 
  for(i.cohort in 1:ncohort){ 
piTrue$rp2d.1[piTrue$sim==i.sim&piTrue$cohort==i.cohort] <- 
piTrue$dose[which.max(piTrue$pi[piTrue$sim==i.sim&piTrue$cohort==i.
cohort][piTrue$pi[piTrue$sim==i.sim&piTrue$cohort==i.cohort] <= 
pi.target])] 
  } 
} 
 
### 2. rp2d is the dose of which pi is closest pi.target 
piTrue$diff <- abs(piTrue$pi-pi.target) 
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for(i.sim in 1:n.sim){ 
  for(i.cohort in 1:ncohort){ 
piTrue$rp2d.2[piTrue$sim==i.sim&piTrue$cohort==i.cohort] <- 
piTrue$dose[which.min(piTrue$diff[piTrue$sim==i.sim&piTrue$cohort==i
.cohort])] 
  } 
} 
 
write.csv(piTrue, "3cohort_piTrue.csv",row.names = FALSE) 
 
piTrue <- read.csv("3cohort_piTrue.csv") 
 
## for pi estimates of last observation 
lastObs.p <- filter(all.psum,id==n.max) 
 
for(i in 1:nrow(lastObs.p)){ 
lastObs.p$pi.true[i] <- 
piTrue$pi[piTrue$sim==lastObs.p$sim[i]&piTrue$cohort==lastObs.p$cohor
t[i]&piTrue$dose==lastObs.p$dose[i]] 
} 
## check coverage of true pi. 
for(i in 1:nrow(lastObs.p)){ 
if(lastObs.p$pi.true[i] <= lastObs.p$p.95[i] & lastObs.p$mean[i] >= 
lastObs.p$p.05[i]){ 
lastObs.p$contain[i] <- 1 } 
else{ 
lastObs.p$contain[i] <- 0 
  } 
} 
 
coverage.pi <- 
ddply(lastObs.p,.(sim,cohort,dose),summarise,contain.pi=length(mean[contai
n==1]),trial=length(tr)) 
coverage.pi$coverage <- coverage.pi$contain.pi/coverage.pi$trial 
write.csv(coverage.pi, "3cohort_rule_coverage_pi_120.csv",row.names = 
FALSE) 
 
coverage.40 <- read.csv("3cohort_rule_coverage_pi_40.csv") 
coverage.80 <- read.csv("3cohort_rule_coverage_pi_80.csv") 
coverage.120 <- read.csv("3cohort_rule_coverage_pi_120.csv") 
 
###plot for coverage of true pi. 
### data management 
 
coverage.40$sample <- 1 # 1 means sample size is 40 
coverage.80$sample <- 2 # 2 means sample size is 80 
coverage.120$sample <- 3 # 3 means sample size is 120 
 
coverage.40.80.120 <- rbind(coverage.40,coverage.80,coverage.120) 
 
for(i in 1:nrow(coverage.40.80.120)){ 
coverage.40.80.120$pi.true[i] <- 
piTrue$pi[piTrue$sim==coverage.40.80.120$sim[i] & 
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piTrue$cohort==coverage.40.80.120$cohort[i] & 
piTrue$dose==coverage.40.80.120$dose[i]] 
} 
 
write.csv(coverage.40.80.120, 
"3cohort_coverage_pi_40_80_120.csv",row.names = FALSE) 
 
coverage.40.80.120 <- read.csv("3cohort_coverage_pi_40_80_120.csv") 
 
### plot 
coverage.40.80.120$sample <- factor(coverage.40.80.120$sample, 
levels = c(1:3), 
labels = c("Sample 1", "Sample 
2","Sample 3")) 
coverage.40.80.120$sim <- factor(coverage.40.80.120$sim, 
levels = c(1:n.sim), 
labels = c("Simulation 1", "Simulation 
2","Simulation 3")) 
coverage.40.80.120$cohort <- factor(coverage.40.80.120$cohort, 
levels = c(1:ncohort), 
labels = c("Group 1", "Group 
2","Group 3")) 
 
ggplot(data=coverage.40.80.120,  
aes(x=pi.true,y=coverage,colour=cohort,group=cohort))+ 
facet_grid(sample~sim)+theme_bw()+  
geom_point(size=3,pch=18)+geom_line()+ 
theme(legend.title=element_blank(),legend.text=element_text(size=1
6,family="Times New Roman"), 
plot.title = element_text(hjust = 0.5,size=20,family="Times New 
Roman"), 
plot.subtitle = element_text(size=18,family = "Times New Roman"), 
axis.title = element_text(size=18,family="Times New Roman"), 
axis.text = element_text(size=14,family="Times New Roman"), 
strip.text=element_text(size=16,family="Times New Roman"))+  
labs(list(x="True P(DLT)",y="Percentage of CI coverage of true 
P(DLT)", 
subtitle="Patient's probability to be assigned to each group = 
0.2, 0.35, 0.45 \n 90% Credible interval coverage"))+ 
scale_y_continuous(limits = c(0.8,1),labels = scales::percent)+ 
scale_x_continuous(breaks=pretty(coverage.40.80.120$pi.true, n = 
6))+ 
geom_hline(yintercept=0.9,colour="brown") 
         
 
# 2. estimate parameters. 
 
## created dataset with last observations. 
lastObs <- filter(ok.trial,id==n.max) 
 
for(j in 1:n.sim){ 
  lastObs$a1[lastObs$sim==j] <- a1[j] 
  lastObs$d1[lastObs$sim==j] <- d1[j]  
  lastObs$d2[lastObs$sim==j] <- d2[j]  
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} 
 
## to see if alpha1 credible interval contains true alpha1,delta1 and 
#delta2 
for(i in 1:nrow(lastObs)){ 
if(lastObs$alpha1.05[i] <= lastObs$a1[i] & 
lastObs$a1[i]<=lastObs$alpha1.95[i]){ 
lastObs$contain.a1[i] <- 1} 
else{ 
lastObs$contain.a1[i] <- 0} 
   
  
if(lastObs$delta1.05[i]<=lastObs$d1[i]&lastObs$d1[i]<=lastObs$delta1.95[i]
){ 
lastObs$contain.d1[i] <- 1} 
  else{ 
lastObs$contain.d1[i] <- 0} 
   
if(lastObs$delta2.05[i]<=lastObs$d2[i]&lastObs$d2[i]<=lastObs$delta2.95[i]
){ 
lastObs$contain.d2[i] <- 1} 
else{ 
lastObs$contain.d2[i] <- 0} 
} 
 
coverage <- 
ddply(lastObs,.(sim),summarise,alpha1=length(alpha1[contain.a1==1]), 
delta1=length(delta1[contain.d1==1]),delta2=length(delta2[contain.d
2==1])) 
coverage$a1p <- coverage$alpha1/oktrial.number$trial.number 
coverage$d1p <- coverage$delta1/oktrial.number$trial.number 
coverage$d2p <- coverage$delta2/oktrial.number$trial.number 
 
write.csv(coverage, "3cohort_coverage_parameters_120.csv", 
row.names = FALSE) 
 
 
###plot for 3 sample sizes 
cov.para.40 <- read.csv("3cohort_coverage_parameters_40.csv") 
cov.para.80 <- read.csv("3cohort_coverage_parameters_80.csv") 
cov.para.120 <- read.csv("3cohort_coverage_parameters_120.csv") 
 
cov.para.40$sample <- 1 # sample size: 40 
cov.para.80$sample <- 2 # sample size: 40 
cov.para.120$sample <- 3 # sample size: 120 
 
cov.para <- rbind(cov.para.40,cov.para.80,cov.para.120) 
 
write.csv(cov.para,"coverage_parameter.csv",row.names = FALSE) 
 
cov.para$sample <- factor(cov.para$sample, 
                          levels = c(1:3), 
                          labels = c("Sample 1", "Sample 2", "Sample 3"))  
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ggplot(cov.para, aes(sim,a1p)) + theme_bw()+ 
geom_point(stat = "identity") + facet_grid(.~sample)+ 
labs(list(title = "Coverage of alpha1", x = "Simulation", y = 
"Proportion of trials", 
subtitle="Patient's probability to be assigned to each group = 0.2, 
0.35 0.45"))+ 
ylim(0.8,1)+ 
scale_x_continuous(breaks=seq(0,n.sim,1)) +  
theme(legend.title=element_blank(),legend.text=element_text(size=16,
family="Times New Roman"), 
plot.title = element_text(hjust = 0.5,size=20,family="Times New 
Roman"), 
plot.subtitle = element_text(size=18,family = "Times New Roman"), 
axis.title = element_text(size=18,family="Times New Roman"), 
axis.text = element_text(size=16,family="Times New Roman"), 
strip.text=element_text(size=18,family="Times New Roman"))+ 
geom_line()+ 
geom_hline(yintercept=0.9, colour="brown") 
 
ggplot(cov.para, aes(sim,d2p)) + theme_bw()+ 
geom_point(stat = "identity") + facet_grid(.~sample)+ 
labs(list(title = "Coverage of delta2", x = "Simulation", y = 
"Proportion of trials", 
subtitle="Patient's probability to be assigned to each group = 0.2, 
0.35, 0.45"))+ 
ylim(0.8,1)+ 
scale_x_continuous(breaks=seq(0,n.sim,1)) +  
theme(legend.title=element_blank(),legend.text=element_text(size=16,
family="Times New Roman"), 
plot.title = element_text(hjust = 0.5,size=20,family="Times New 
Roman"), 
plot.subtitle = element_text(size=18,family = "Times New Roman"), 
axis.title = element_text(size=18,family="Times New Roman"), 
axis.text = element_text(size=16,family="Times New Roman"), 
strip.text=element_text(size=18,family="Times New Roman"))+ 
geom_line()+ 
geom_hline(yintercept=0.9, colour="brown") 
 
#2.in-trial patient allocation 
### calcualate patient proportion for at each dose level for each cohort 
patient.dlt.proportion <-  
ddply(ok.trial,.(sim,cohort,dose),summarise,patients=length(id), 
dlt.number=length(dlt[dlt==1])) 
patient.dlt.proportion2 <- 
ddply(patient.dlt.proportion,.(sim,cohort),summarise, 
patients=sum(patients),dlt=sum(dlt.number)) 
proportion <- 
merge(patient.dlt.proportion,patient.dlt.proportion2,by=c("sim","cohort")) 
proportion$patient.prop <- proportion$patients.x/proportion$patients.y 
proportion$dlt.prop <- proportion$dlt.number/proportion$dlt 
 
for(i in 1:nrow(proportion)){ 
  proportion$rp2d.1[i] <- piTrue$rp2d.1[i] 
  proportion$rp2d.2[i] <- piTrue$rp2d.2[i] 
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} 
 
for (i in 1:nrow(proportion)){ 
  if(proportion$dose[i] == proportion$rp2d.2[i]){ 
    proportion$match1[i] <- max(proportion$patient.prop)+0.05 
  } else{ 
    proportion$match1[i] <- NA 
  } 
} 
 
write.csv(proportion, "3cohort_patient_proportion.csv",row.names = FALSE) 
 
#### patient proportion plot 
proportion$sim <- factor(proportion$sim, 
                   levels = c(1:n.sim), 
                   labels = c("Sim 1", "Sim 2", "Sim 3"))  
proportion$cohort <- factor(proportion$cohort, 
                      levels = c(1:ncohort), 
                      labels = c("Group 1", "Group 2", "Group 3"))  
 
 
#### patient proportion plot for 3 sample sizes 
 
proportion.40 <- read.csv("3cohort_patient_proportion40.csv") 
proportion.80 <- read.csv("3cohort_patient_proportion80.csv") 
proportion.120 <- read.csv("3cohort_patient_proportion120.csv") 
 
proportion.40$sample <- 1 # sample size: 40 
proportion.80$sample <- 2 # sample size: 80 
proportion.120$sample <- 3 # sample size: 120 
 
proportion.40.80.120 <- rbind(proportion.40,proportion.80,proportion.120) 
 
write.csv(proportion.40.80.120,"proportion_4080120.csv",row.names = FALSE) 
proportion.40.80.120 <- read.csv("proportion_4080120.csv") 
 
proportion.40.80.120$sim <- factor(proportion.40.80.120$sim, 
levels = c(1:n.sim), 
labels = c("Simulation 1", "Simulation 
2", "Simulation 3"))  
proportion.40.80.120$cohort <- factor(proportion.40.80.120$cohort, 
levels = c(1:ncohort), 
labels = c("Group 1", "Group 2", 
"Group 3")) 
 
proportion.40.80.120$sample <- factor(proportion.40.80.120$sample, 
levels = c(1:3), 
labels = c("Sample 1", "Sample 2", 
"Sample 3"))  
 
ggplot(proportion.40.80.120, aes(dose,patient.prop, fill=cohort)) +  
theme_bw()+ 
geom_bar(position="dodge",stat = "identity",width = 0.5) + 
facet_grid(sample~sim)+ 
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labs(list(title = "In-trial dose allocation", x = "Dose level", y = 
"Proportion of patients", 
subtitle="Patient's probability to be assigned to each group = 0.2, 
0.35, 0.45"))+ 
scale_x_continuous(breaks=seq(0,nlevel,1)) +  
theme(legend.title=element_blank(),legend.text=element_text(size=16
,family="Times New Roman"), 
plot.title = element_text(hjust = 0.5,size=20,family="Times New 
Roman"), 
plot.subtitle = element_text(size=18,family = "Times New Roman"), 
axis.title = element_text(size=18,family="Times New Roman"), 
axis.text = element_text(size=16,family="Times New Roman"), 
strip.text=element_text(size=15.5,family="Times New Roman"))+ 
geom_point(aes(dose,match1,colour=cohort),shape=25,size=1.5,positio
n=position_dodge(.5),stat = "identity")+ 
ylim(0,0.5) 
 
# 3--- calculate and plot number of DLTs/proportion for all dose levels in 
3 simulations 
## 3.1 --calculate number dlt for all dose levels and cohorts 
dlt.trial <- 
ddply(ok.trial,.(sim,tr,dose),summarise,dlt=length(dlt[dlt==1])) 
dlt.trial.sum <- ddply(dlt.trial,.(sim,dose),summarise,dlt.5=median(dlt), 
dlt.25=quantile(dlt, 
0.25),dlt.75=quantile(dlt,0.75)) 
 
overall.dltprop <- ddply(dlt.trial,.(sim,tr),summarise,dlt=sum(dlt)) 
overall.dltprop$dltprop <- overall.dltprop$dlt/n.max 
overall.dltprop.sum <- 
ddply(overall.dltprop,.(sim),summarise,mean=mean(dltprop), 
median=median(dltprop),p25=quantile(dltprop, 
0.25),p75=quantile(dltprop,0.75)) 
 
## export datasets 
write.csv(dlt.trial, "3cohort_dlt_trial.csv",row.names = FALSE) 
write.csv(dlt.trial.sum, "3cohort_dlt_trial_sum.csv",row.names = FALSE) 
write.csv(overall.dltprop.sum, "3cohort_dltprop_sum.csv",row.names = 
FALSE) 
 
 
### 3.2--DLT plot 
dlt.trial.sum$sim <- factor(dlt.trial.sum$sim, 
levels = c(1:n.sim), 
labels = c("Simulation 1", "Simulation 2", 
"Simulation 3"))  
 
#### DLT plot for 3 sample sizes 
dlt.trial.sum.40 <- read.csv("3cohort_40_dlt_trial_sum.csv") 
dlt.trial.sum.80 <- read.csv("3cohort_80_dlt_trial_sum.csv") 
dlt.trial.sum.120 <- read.csv("3cohort_120_dlt_trial_sum.csv") 
 
dlt.trial.sum.40$sample <- 1 # sample size: 40 
dlt.trial.sum.80$sample <- 2 # sample size: 80 
dlt.trial.sum.120$sample <- 3 # sample size: 120 
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dlt.trial.sum.40.80.120 <- 
rbind(dlt.trial.sum.40,dlt.trial.sum.80,dlt.trial.sum.120) 
 
write.csv(dlt.trial.sum.40.80.120,"dltsum_4080120.csv",row.names = FALSE) 
 
dlt.trial.sum.40.80.120 <- read.csv("dltsum_4080120.csv") 
 
dlt.trial.sum.40.80.120$sim <- factor(dlt.trial.sum.40.80.120$sim, 
levels = c(1:n.sim), 
labels = c("Simulation 1", 
"Simulation 2", 
"Simulation 3"))  
dlt.trial.sum.40.80.120$sample <- factor(dlt.trial.sum.40.80.120$sample, 
levels = c(1:3), 
labels = c("Sample 1", "Sample 
2", "Sample 3")) 
 
ggplot(dlt.trial.sum.40.80.120, aes(dose,dlt.5)) + 
theme_bw()+ 
geom_errorbar(aes(x=dose, y=dlt.5, ymin=dlt.25, 
ymax=dlt.75),position="dodge",stat = "identity")+ 
facet_grid(sample~sim)+ 
labs(list(title = "DLTs at all dose levels among 100 trials", x = 
"Dose level", y = "Number of DLTs", 
subtitle="Patient's probability to be assigned to each group = 0.2, 
0.35, 0.45"))+ 
scale_x_continuous(breaks=seq(0,nlevel,1)) +  
scale_y_continuous(breaks=pretty(dlt.trial.sum.40.80.120$dlt.75,  
n = 8))+ 
theme(legend.title=element_blank(),legend.text=element_text(family=
"Times New Roman",size=16), 
plot.title = element_text(hjust = 0.5,family="Times New 
Roman",size=20), 
plot.subtitle = element_text(size=18,family = "Times New Roman"), 
axis.title = element_text(size=18,family="Times New Roman"), 
axis.text = element_text(size=16,family="Times New Roman"), 
strip.text=element_text(size=15.5,family="Times New Roman"))+ 
geom_point(aes(dose,dlt.5),shape=20,size=3,stat = "identity") 
 
#### overall DLT prop plot 3 sample sizes 
overall.dltprop.sum.40 <- read.csv("3cohort_40_dltprop_sum.csv") 
overall.dltprop.sum.80 <- read.csv("3cohort_80_dltprop_sum.csv") 
overall.dltprop.sum.120 <- read.csv("3cohort_120_dltprop_sum.csv") 
 
overall.dltprop.sum.40$sample <- 1 # sample size: 40 
overall.dltprop.sum.80$sample <- 2 # sample size: 40 
overall.dltprop.sum.120$sample <- 3 # sample size: 120 
overall.dltprop.sum.40.80.120 <-  
rbind(overall.dltprop.sum.40,overall.dltprop.sum.80,overall.dltprop.sum.12
0) 
 
write.csv(overall.dltprop.sum.40.80.120,"dltprop_sum.csv", 
row.names = FALSE) 
 
 89 
overall.dltprop.sum.40.80.120 <- read.csv("dltprop_sum.csv") 
 
overall.dltprop.sum.40.80.120$sample <- 
factor(overall.dltprop.sum.40.80.120$sample, 
levels = c(1:3), 
labels = c("Sample 1", "Sample 2", "Sample 3")) 
 
ggplot(overall.dltprop.sum.40.80.120, aes(sim,mean)) + 
theme_bw()+ 
geom_errorbar(aes(x=sim, y=mean, ymin=p25, 
ymax=p75),position="dodge",stat = "identity")+ 
facet_grid(.~sample)+ 
labs(list(title = "Overall DLT proportion among 100 trials in each 
simulaiton", x = "Simulation", y = "Proportion of DLTs", 
subtitle="Patient's probability to be assigned to each group = 0.2, 
0.35, 0.45"))+ 
scale_x_continuous(breaks=seq(0,n.sim,1)) +  
ylim(0,0.4)+ 
theme(legend.title=element_blank(),legend.text=element_text(family=
"Times New Roman",size=16), 
plot.title = element_text(hjust = 0.5,family="Times New 
Roman",size=20), 
plot.subtitle = element_text(size=18,family = "Times New Roman"), 
axis.title = element_text(size=18,family="Times New Roman"), 
axis.text = element_text(size=16,family="Times New Roman"), 
strip.text=element_text(size=18,family="Times New Roman"))+ 
geom_point(aes(x=sim,y=mean),colour="blue",shape=16,size=3)+ 
geom_point(aes(x=sim,y=median),colour="brown",shape=18,size=3) 
 
# 4---% Trial each dose is chosen as target  
#---Largest dose with P(DLT)<=pi.target 
ps <- ddply(ok.trial,.(sim,tr,dose,cohort),summarise,ps=mean(dlt)) 
rp2d.largest <- ddply(ps[ps$ps<=pi.target,],.(sim,tr,cohort),summarise, 
rp2d.largest=max(dose)) 
colnames(rp2d.largest)[4] <- 'dose' 
trial.target.largest <- ddply(rp2d.largest,.(sim,cohort,dose),summarise, 
trial.number=length(unique(tr))) 
for(i in 1:n.sim){ 
  for(j in 1:ncohort){ 
trial.target.largest$target[trial.target.largest$sim==i & 
trial.target.largest$cohort==j] <- 
piTrue$rp2d.2[piTrue$sim==i&piTrue$cohort==j][1] 
  } 
} 
 
for(i in 1:n.sim){ 
trial.target.largest$totaltrial[trial.target.largest$sim==i] <- 
oktrial.number$trial.number[oktrial.number$sim==i] 
} 
 
trial.target.largest$trial.prop <-  
trial.target.largest$trial.number/trial.target.largest$totaltrial 
 
for(i in 1:nrow(trial.target.largest)){ 
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  if(trial.target.largest$dose[i]==trial.target.largest$target[i]){ 
trial.target.largest$match[i] <- 
max(trial.target.largest$trial.prop)+0.05} 
  else {trial.target.largest$match[i] <- NA} 
} 
 
write.csv(trial.target.largest, 
"3cohort_recommend_largest120.csv",row.names = FALSE) 
 
### plot Largest dose with P(DLT)<=pi.target for 3 sample sizes 
rec.largest.40 <- read.csv("3cohort_recommend_largest40.csv") 
rec.largest.80 <- read.csv("3cohort_recommend_largest80.csv") 
rec.largest.120 <- read.csv("3cohort_recommend_largest120.csv") 
 
rec.largest.40$sample <- 1 # sample size: 40 
rec.largest.80$sample <- 2 # sample size: 40 
rec.largest.120$sample <- 3 # sample size: 120 
 
rec.largest.40.80.120 <- 
rbind(rec.largest.40,rec.largest.80,rec.largest.120) 
 
write.csv(rec.largest.40.80.120,"recommend_largest_sum.csv", 
row.names = FALSE) 
 
#rec.largest.40.80.120 <- read.csv("recommend_largest_sum.csv") 
 
rec.largest.40.80.120$sim <- factor(rec.largest.40.80.120$sim, 
                                    levels = c(1:n.sim), 
labels = c("Simulation 1",  
"Simulation 2",  
"Simulation 3"))  
rec.largest.40.80.120$sample <- factor(rec.largest.40.80.120$sample, 
                                       levels = c(1:3), 
labels = c("Sample 1",  
"Sample 2",  
"Sample 3")) 
rec.largest.40.80.120$cohort <- factor(rec.largest.40.80.120$cohort, 
                                       levels = c(1:ncohort), 
labels = c("Group 1",  
"Group 2",  
"Group 3")) 
 
ggplot(rec.largest.40.80.120, aes(dose,trial.prop, fill=cohort)) + 
theme_bw()+ 
geom_bar(position="dodge",stat = "identity",width = 0.5) + 
facet_grid(sample~sim)+ 
labs(list(title = "Final recommended dose distribution among 3 groups",  
subtitle="Patient's probability to be assigned to each group = 
0.2, 0.35, 0.45 \nLargest dose with P(DLT) <= target P(DLT)",x = 
"Dose level", y = "Proportion of trials")) + 
scale_x_continuous(breaks=seq(0,nlevel,1)) +  
scale_y_continuous(limits = c(0,0.6),breaks = seq(0, 0.6, by = 0.1))+ 
theme(legend.title=element_blank(), plot.title = element_text(hjust = 
0.5))+ 
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geom_point(aes(dose,match,colour=cohort),shape=25,size=1.5, 
position=position_dodge(.5),stat ="identity")+ 
theme(legend.title=element_blank(),legend.text=element_text(family="Tim
es New Roman",size=11), 
plot.title = element_text(hjust = 0.5,family="Times New 
Roman",size=20), 
plot.subtitle = element_text(size=16,family = "Times New Roman"), 
axis.title = element_text(size=16,family="Times New Roman"), 
axis.text = element_text(size=16,family="Times New Roman"), 
strip.text=element_text(size=16,family="Times New Roman")) 
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